Oral film comprising lurasidone

By designing an oral film containing lurasidone, polyvinyl alcohol-polyethylene glycol graft copolymer and polyvinyl alcohol of a specific molecular weight, the problems of difficult swallowing and poor compliance of lurasidone tablets have been solved, achieving rapid disintegration, soft texture and high bioavailability of lurasidone delivery.

CN119033737AInactive Publication Date: 2024-11-29SHENZHEN BEIMEI PHARM CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411132046.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-08-17
Filing Date
2024-08-16
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing lurasidone tablets are difficult to swallow, especially unsuitable for children and elderly patients. Furthermore, patients in the acute phase of schizophrenia often refuse to take the medication. Traditional dosage forms have poor adherence, and the fragility of the membrane and the long disintegration time caused by the high active agent load affect bioequivalence and patient experience.

Method used

The oral film design incorporates lurasidone or a pharmaceutically acceptable salt thereof, a polyvinyl alcohol-polyethylene glycol graft copolymer, and polyvinyl alcohol of a specific molecular weight, ensuring high active agent loading, soft texture, rapid disintegration, and stability. The matrix layer, containing the polyvinyl alcohol-polyethylene glycol graft copolymer and polyvinyl alcohol, provides good film-forming properties and stability.

Benefits of technology

A lurasidone oral film, bioequivalent to a 40mg tablet, has been developed. It features rapid disintegration, a soft texture, good stability, and no stickiness, making it suitable for children and elderly patients and improving compliance and bioavailability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005001134990000011
    Figure BDA0005001134990000011
  • Figure BDA0005001134990000101
    Figure BDA0005001134990000101
  • Figure BDA0005001134990000102
    Figure BDA0005001134990000102
Patent Text Reader

Abstract

The present invention relates to an oral film comprising a matrix layer wherein the matrix layer comprises lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol having an average molecular weight of 20,000-250,000 g / mol, a method for preparing the oral film, and a method for preparing the oral film. And to the use of such oral films as a medicament, in particular in the treatment of schizophrenia, depression and / or bipolar disorder.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to an oral film comprising lurasidone or a pharmaceutically acceptable salt thereof, a method for preparing the oral film and the use of such an oral film as a medicament, in particular in the treatment of schizophrenia, depression and / or bipolar disorder. Background Art

[0002] Oral thin films are thin films containing at least one pharmaceutically active agent that may be in the form of a smooth film or a foamed film, which is placed directly into the oral cavity or against the oral mucosa (e.g., toward the tongue, under the tongue, toward the gums, toward the cheeks), and dissolves or disintegrates there, thereby delivering the active agent over a period of time. In particular, these films are polymer-based films containing active agents that can achieve active agent delivery by directly releasing the active agent from the oral thin film to the mucosa, indirectly delivering the active agent via dissolution in saliva for absorption in the gastrointestinal tract (GI), or a combination of both.

[0003] The active agent may be dissolved, emulsified or dispersed in the film.

[0004] As explained in more detail further below, the oral film according to the present invention contains lurasidone or a pharmaceutically acceptable salt thereof as a pharmaceutically active agent and is preferably used for the treatment of schizophrenia, depression and / or bipolar disorder.

[0005] Lurasidone is a compound having the following formula (I), known by its systematic name (3aR,4S,7R,7aS)-2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-4,7-methylene-2H-isoindole-1,3-dione, (1R,2S,6R,7S)-4-[[( 1S,2S)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione, or N-(2-(4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide.

[0006]

[0007] Lurasidone was developed by Dainippon Sumitomo Pharma and marketed under the trade name The second-generation antipsychotic drug marketed as 20mg, 40mg, 60mg, 80mg and 120mg oral tablets was approved by the U.S. Food and Drug Administration (FDA) on October 28, 2010 for the treatment of schizophrenia and bipolar disorder, among others. Subsequently, the FDA also approved lurasidone for the treatment of major depressive episodes associated with bipolar I disorder in children and adolescents aged 10-17 years, as well as an expanded indication for the treatment of bipolar depression in adults as a single agent or in combination with lithium / valproate.

[0008] As an atypical antipsychotic, lurasidone has a unique mechanism of action, definite efficacy, high safety, little impact on body weight and metabolic indicators, once-a-day administration, and convenient administration compared to similar drugs. Compared with traditional antipsychotics, lurasidone is less likely to cause extrapyramidal symptoms (EPS) and has been used as a first-line antipsychotic due to its wider indications, fewer toxic side effects, and ability to improve patients' cognition.

[0009] Lurasidone belongs to the chemical class of piperidinyl-benzisoxazole derivatives. It has high affinity for dopamine D2-receptors as well as serotonergic 5HT2A and 5-HT7 receptors. In addition, it also inhibits α2c-adrenergic receptors and α2a-adrenergic receptors. Lurasidone also exhibits some partial agonist effects on 5HT1A receptors. Moreover, lurasidone does not bind to cholinergic or muscarinic receptors in humans.

[0010] Currently, lurasidone is only available in tablet form, which is difficult to swallow and is therefore not suitable for children and elderly patients. In addition, tablets are inconvenient for patients to take without water. Moreover, in the acute phase of schizophrenia, patients often refuse to take medication, may hide the medication in their mouths or vomit it out, so medication compliance issues are common among schizophrenia patients. Therefore, dosage forms such as tablets and capsules are often ineffective, and convenient dosage forms should be considered for patients with schizophrenia. Therefore, it is necessary to provide a new formulation that is easy to use and has good compliance to solve the above problems.

[0011] As described above, oral thin films have certain advantages over tablets, and therefore one object of the present invention is to provide an oral thin film for administering lurasidone that is comparable to commercially available Tablets are bioequivalent.

[0012] Since 40mg The tablet contains 40 mg of lurasidone hydrochloride in an insoluble form (equivalent to 37.2 mg of lurasidone), so the oral film should also be designed in such a way that it can contain at least 40 mg of lurasidone hydrochloride in a single oral film, which is a relatively high dose for the oral film, wherein lurasidone is preferably present in an insoluble, i.e. suspended, form in the oral film.

[0013] High active agent loads in oral films are a known problem, since this can lead to brittle films or can directly prevent the polymers contained from forming a film. In particular, the use of hydroxypropylmethylcellulose (HPMC) tends to lead to brittle films. In order to still be able to prepare suitable films with HPMC, large oral films or oral films with very large layer thicknesses are generally required. However, large or thick oral films have the disadvantage that they cause problems in application, may give the patient a foreign body sensation, and may exhibit long disintegration times.

[0014] However, depending on the actual application, a long disintegration time is not desirable. For lurasidone, rapid disintegration is preferred to facilitate swallowing of the disintegrated film in a short time, which will result in delivery of the active substance via the oral / GI route. Without wishing to be bound by theory, due to the low solubility of the active substance, it is believed that the release of the active substance is primarily controlled by drug dissolution in the gastrointestinal tract, making the oral / GI route more suitable for achieving similar results as oral administration. Bioequivalence of tablets is important.

[0015] Furthermore, the higher the active agent loading, the more film-forming polymer must be included. This results in a greater area density / area weight of the film, which results in longer drying times. However, extended drying times are uneconomical and may also result in uneven distribution of the active agent within the oral film.

[0016] Furthermore, unless an appropriate polymer is selected, in many cases, also depending on the polymer used, an oral film having a high area density exhibits an unpleasant feel to the patient when administered into the patient's oral cavity.

[0017] In addition, the use of certain polymers for forming oral films, such as HPMC, enables the incorporation of large amounts of active agents. But in that case, large amounts of HPMC are also required to provide acceptable oral films. If high concentrations of HPMC polymers are used, they exhibit a persistent sticky feel in the patient's mouth, which should be avoided.

[0018] Therefore, despite the advantages of OTF, several challenges remain in formulating effective oral thin films for lurasidone. Lurasidone is poorly water soluble and has a bitter taste, which can affect the acceptability and efficacy of the formulation. Ensuring uniform distribution of the drug within the film matrix is ​​another important consideration.

[0019] In conclusion, alternative dosing options for lurasidone are highly desirable that overcome the disadvantages of administration in tablet form. As discussed above, OTF will be able to address these disadvantages.

[0020] Therefore, there is a need in the art for lurasidone oral thin films. SUMMARY OF THE INVENTION

[0022] The object of the present invention is to overcome the above-mentioned disadvantages of the prior art. In particular, the object of the present invention is to provide a method for administering a large amount of lurasidone or a pharmaceutically acceptable salt thereof and Tablets, especially with The oral film should preferably be an oral film that is bioequivalent to the 40 mg tablet. In addition, the oral film should have an acceptable disintegration time, and the pharmaceutically active agent should be evenly distributed in the oral film. Further, the oral film should preferably be characterized by a pleasant and soft texture, and thus preferably will not induce a foreign body sensation in the patient after administration, and in particular any persistent sticky sensation in the patient's oral cavity should be avoided. Moreover, the oral film should be relatively stable, and should also be relatively stable over an extended storage period of, for example, one month.

[0023] Another object of the present invention is to provide an oral thin film (OTF) formulation that can effectively mask the bitter taste of lurasidone and ensure a pleasant taste to improve patient compliance.

[0024] Moreover, it is easy to carry, has excellent clinical compliance, is particularly suitable for children and elderly patients, or for use in acute episodes of psychosis, and exhibits excellent disintegration properties and high bioavailability.

[0025] Furthermore, it would be possible to prepare an oral thin film with a uniform drug distribution throughout the OTF as easily and economically as possible.

[0026] The above objects are solved by an oral film comprising a matrix layer, wherein the matrix layer comprises lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer, and at least one polyvinyl alcohol having an average molecular weight of 20,000 to 250,000 g / mol, in particular 20,000 to 40,000 g / mol.

[0027] Such oral films show The 40 mg tablets are bioequivalent because an oral film with reasonable size and reasonable area density can provide a dose of 40 mg of lurasidone HCl (equivalent to 37.2 mg of lurasidone).

[0028] It has been found that polyvinyl alcohol-polyethylene glycol graft copolymers and polyvinyl alcohol still have good film-forming properties if a large amount of suspended / dispersed active agent is present in the formulation.

[0029] This has also been observed in polyvinyl alcohol, where the effect is to some extent even more pronounced. However, films based solely on polyvinyl alcohol are hard and therefore have a texture that is unpleasant for the patient.

[0030] In contrast, films based solely on polyvinyl alcohol-polyethylene glycol graft copolymers have a softer texture because the polymers themselves form softer films. However, these films are not as stable.

[0031] Due to the polyvinyl alcohol-polyethylene glycol graft copolymer and polyvinyl alcohol with a defined molecular weight, it has been possible to produce films characterized by a high active agent loading, a soft texture with the polyvinyl alcohol-polyethylene glycol graft copolymer film, and a stability approaching that of the polyvinyl alcohol film.

[0032] Polyvinyl alcohols with higher molecular weights are suitable for forming oral films with high active agent loadings. However, polyvinyl alcohols with higher molecular weights have previously been reported to result in longer disintegration times, which is undesirable for oral films according to the present invention.

[0033] The present inventors surprisingly discovered that, contrary to previous preliminary findings, high molecular weight polyvinyl alcohol can also be used to formulate lurasidone oral films with acceptable disintegration times.

[0034] The polyvinyl alcohol-polyethylene glycol graft copolymer preferably forms the basic structure and decisively determines the properties of the film, while the polyvinyl alcohol serves as an additional stabilizer.

[0035] This enables high active agent loadings to be achieved with layer thicknesses and film dimensions within acceptable ranges. Disintegration times are also within acceptable ranges, with the acceptable range preferably including values ​​of less than 1 minute, or in particular less than 45 seconds.

[0036] Furthermore, the oral thin film according to the present invention does not cause a sticky feeling in the patient's oral cavity after administration.

[0037] Furthermore, such an oral film is readily accepted by patients, thereby ensuring patient compliance with treatment, and can be prepared simply and economically.

[0038] Preferred embodiments are described in the dependent claims.

[0039] Another aspect of the present invention relates to a method for producing an oral film, comprising the following steps:

[0040] a) preparing a dispersion comprising lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol having an average molecular weight of 20,000 to 250,000 g / mol, in particular 20,000 to 40,000 g / mol;

[0041] b) spreading the dispersion from step a), and

[0042] c) drying the spread dispersion to obtain an oral thin film.

[0043] In another aspect, the present embodiment relates to an oral thin film as described herein and / or as obtained or obtainable by a process disclosed herein, for use as a medicament, preferably for the treatment of psychiatric disorders, in particular schizophrenia, depression and / or bipolar disorder.

[0044] The following description provides some embodiments of the present invention and is not intended to limit the scope, applicability or configuration of the invention or multiple inventions. Various changes may be made to the function and arrangement of the elements without departing from the scope of the invention described herein. Some embodiments may be implemented without all the specific details.

[0045] Reference will now be made in detail to the embodiments. In the detailed description below, many specific details will be listed to provide a comprehensive understanding of the subject matter of this article. However, it will be apparent to one of ordinary skill in the art that the subject matter can be practiced without these specific details. In other cases, well-known methods, processes, components and systems are not described in detail to avoid unnecessarily obscuring the features of the embodiments. In the following description, it should be understood that the features of one embodiment can be used in combination with the features of another embodiment, wherein the features of the different embodiments are not incompatible.

[0046] definition

[0047] Within the meaning of the present invention, an "oral thin film" (OTF) is a drug delivery system that includes a thin, flexible film designed to dissolve or disintegrate rapidly when placed in the oral cavity. Different routes of administration of oral thin films include tongue administration, sublingual administration, gum administration, buccal administration, oral mucosal administration, and oral administration.

[0048] Lingual administration of a drug or therapeutic agent refers to placing it on the tongue. Sublingual administration involves placing the drug under the tongue. Gingival administration involves taping the drug to the gums. Buccal administration requires placing the drug between the gums and the lining of the cheek. Oromucosal administration refers to delivering a drug or therapeutic agent through the oral mucosa of the mouth. Oral administration involves swallowing the drug, which then passes through the digestive system and is absorbed in the stomach or intestines.

[0049] Unless otherwise indicated, the "average molecular weight" of a polymer disclosed herein refers to the weight average molecular weight (M W ), which is the average molecular weight of a polymer calculated by taking the sum of the molecular weights of all individual polymer chains, weighting each chain by its mass, and dividing by the total mass of the polymer. In other cases, "average molecular weight" refers to the number-average molecular weight M. N , which is the average molecular weight of a polymer calculated by dividing the total weight of the polymer by the total number of polymer molecules.

[0050] Any average molecular weight can be determined by gel permeation chromatography (GPC). In GPC, a polymer sample is dissolved in a suitable solvent and passed through a column filled with a porous gel. The molecules are separated based on their size, with larger molecules eluting first because they are less entangled in the pores of the porous gel. The elution curve is detected by appropriate means (e.g., a UV-Vis detector) and analyzed to determine the molecular weight distribution, from which the M can be calculated using a calibration curve. N and M W .

[0051] Within the meaning of the present invention, the term "therapeutically effective amount" refers to the amount of active agent in the oral film that, if administered to a patient via the oral film, is sufficient to provide a blood level of lurasidone in a similar range (e.g., from about 10% to about 1000%, as measured by AUC) when compared to the blood level obtained with a single administration of 40 mg of oral lurasidone. Within the meaning of the present invention, the terms "active", "active agent", etc. and the term "lurasidone" refer to lurasidone in any pharmaceutically acceptable chemical form and morphological form and physical state. These forms include, but are not limited to, lurasidone in free, dissociated or any associated form such as hydrates, solvates, salts, etc., and lurasidone in particulate form, which may be a micronized form, a crystalline form, particularly one of its polymorphic forms and / or an amorphous form, and any hybrid type form of any of the foregoing forms or a mixture thereof. When lurasidone is contained in a medium such as a solvent, it may be dissolved or dispersed or partially dissolved and partially dispersed.

[0052] When it is mentioned that lurasidone is used in a particular form in the manufacture of an OTF, this does not exclude that this form of lurasidone interacts with other components of the OTF such that the active substance is present in another form in the final OTF. This means that even if lurasidone is included in the OTF in a free, dissociated form, it may be present in the final OTF in the form of a hydrate or solvate, or, if it is included in the OTF in one of its polymorphic forms, it may be present in the final oral film in an amorphous form.

[0053] The lurasidone starting material included in the oral film during the manufacturing process of the oral film may be in a particulate form. Lurasidone may be present in the OTF, for example, in a particulate, dispersed and / or dissolved form.

[0054] Within the meaning of the present invention, the term "particle" refers to a solid particulate material comprising individual particles whose size is negligible compared to the material. In particular, the particle is a solid, including plastic / deformable solids, including amorphous and crystalline materials.

[0055] Within the meaning of the present invention, the term "dispersion" refers to a step or combination of steps in which the starting material (e.g., lurasidone) is not dissolved or is not completely dissolved. Dispersion in the sense of the present invention includes the dissolution of part of the starting material (e.g., lurasidone particles), which depends on the solubility of the starting material (e.g., the solubility of lurasidone in the dispersion). Most preferably, lurasidone is present in the form of particles during manufacturing and in the final oral film.

[0056] In this context, it also becomes clear that for any layer of the oral film (e.g., backing layer, matrix layer) and for the polymer when cast into a film, terms such as "disintegration", "disintegrable", "disintegrate", etc. should be understood very broadly and not in a strict scientific sense as chemical dissolution of molecules in a solvent. Any transition of the solid state to the liquid state of the relevant layer, such as dispersion, formation of a suspension, gelation of the film and disintegration into smaller gel parts, etc., must be regarded as "disintegration" in the sense of the present invention, as long as the "disintegrated" material is able to move freely in a liquid (e.g., saliva).

[0057] It should be noted that the term "dissolved" with respect to the substance itself, such as the active agent lurasidone or any excipient, will continue to be used in the usual chemical sense of dissolving a molecule in a solvent. For example, lurasidone in dissolved form obviously does not include lurasidone in dispersed form. During the manufacture of the oral film, the polymer itself may be present in the coating composition in dissolved form in the ordinary chemical sense (e.g., not dispersed, in the form of small gel portions, etc.), but in the case of polymer cast into a film, "dissolving" such a film also includes gelation and disintegration of the film into smaller gel portions.

[0058] The matrix layer is the final solidified layer, obtained, for example, after coating and drying the spread dispersion (i.e., the solvent-containing coating composition). The matrix layer can also be made by laminating two or more such solidified layers (e.g., dried layers) of the same composition to provide the required area weight. The matrix layer can be mucoadhesive (in the form of a mucoadhesive layer), or the oral film can contain an additional mucoadhesive mucosal contact layer to provide sufficient adhesion. However, preferably, the matrix layer is not a mucoadhesive layer, and the OTF does not contain such a mucosal contact layer.

[0059] Within the meaning of the present invention, the term "area density" refers to the 2 The total weight of a particular layer (e.g., substrate layer) provided. This value may include residual amounts of process solvents, such as water. The term "area weight" is used synonymously with the term "area density." Due to manufacturing variability, the tolerance for the areal weight value is ±10%, preferably ±7.5%.

[0060] If not indicated otherwise, "%" or "wt. %" refers to weight % based on the total weight of the layer or oral film or the corresponding coating composition used to prepare such a layer, e.g. based on the total weight of the matrix layer, or e.g. based on the total weight of the dispersion.

[0061] In the meaning of the present invention, the term "polymer" generally refers to any substance consisting of repeating units obtained by polymerizing one or more monomers, and includes homopolymers consisting of one type of monomer and copolymers consisting of two or more types of monomers. Polymers can have any structure, such as linear polymers, star polymers, comb polymers, brush polymers, and in the case of copolymers, have any monomer arrangement, such as alternating copolymers, statistical copolymers, block copolymers or grafted polymers. The minimum molecular weight varies according to the polymer type and is known to those skilled in the art. The molecular weight of a polymer can be, for example, higher than 2000 daltons, preferably higher than 5000 daltons, more preferably higher than 10000 daltons. Accordingly, compounds having a molecular weight lower than 2000 daltons, preferably lower than 5000 daltons or more preferably lower than 10000 daltons are generally referred to as oligomers.

[0062] In a more specific sense, the term "polymer" in the context of the substrate layer may also collectively refer to at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol.

[0063] Within the meaning of the present invention, the term "room temperature" refers to the unaltered temperature found in a laboratory room where the experiments are performed, typically within the range of 15°C to 35°C, preferably about 18°C ​​to 25°C.

[0064] Within the meaning of the present invention, the term "patient" refers to a subject who has presented clinical manifestations of one or more specific symptoms indicating a need for treatment, is undergoing preventative or prophylactic treatment for a disorder, or has been diagnosed with a disorder to be treated.

[0065] Within the meaning of the present invention, the term "dispersion" is used synonymously with the term "coating composition" and refers to a composition comprising the matrix layer components in a solvent, which can be coated onto a backing layer (if present) or a release liner to form a matrix layer when dried.

[0066] Within the meaning of the present invention, the term "dissolving" in the context of preparing a coating composition, e.g. dissolving a component of the coating composition (such as an active agent), refers to the process of obtaining a solution which is clear and does not contain any macroscopic particles.

[0067] Within the meaning of the present invention, the term "solvent" refers to any liquid substance, which may be a volatile organic liquid such as methanol, ethanol, isopropanol, acetone, ethyl acetate, dichloromethane, hexane, n-heptane, heptane, toluene and mixtures thereof, but preferably is water.

[0068] Within the meaning of the present invention, unless otherwise indicated, the term "about" refers to an amount of ±10% of the disclosed amount. In some embodiments, the term "about" refers to an amount of ±5% of the disclosed amount. In some embodiments, the term "about" refers to an amount of ±2% of the disclosed amount.

[0069] The terms used in the description of the disclosure herein are only used for the purpose of describing specific embodiments and are not intended to limit the subject matter. The singular forms "a", "an" and "the" used in this specification and the appended claims are intended to also include plural forms, unless the context clearly indicates otherwise. It should also be understood that the term "and / or" used herein refers to and encompasses any and all possible combinations of one or more related listed items. It should be further understood that the terms "includes", "including", "comprises" and / or "comprising" used in this specification indicate the presence of the features, integers, steps, operations, elements and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components and / or groups thereof.

[0070] As used herein, the word "comprising" may also mean "consisting of." BRIEF DESCRIPTION OF THE DRAWINGS

[0071] Figure 1 : Based on the OTF of formula A and Comparison of dissolution time of 40 mg tablets at different pH.

[0072] Figure 2 : Comparison of dissolution time of OTF according to formulation A at different pH. DETAILED DESCRIPTION OF THE INVENTION

[0074] Matrix layer

[0075] The oral film according to the present invention has (at least one) matrix layer, wherein the matrix layer comprises lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol having an average molecular weight of 20,000 to 250,000 g / mol, in particular 20,000 to 40,000 g / mol.

[0076] The oral film according to the present invention comprises lurasidone or a pharmaceutically acceptable salt thereof as an active agent. However, the oral film may further comprise at least one other active agent, which may be selected from the class of active agents of analgesics, hormones, hypnotics, sedatives, antiepileptics, stimulants, psychoneurological drugs, neuromuscular blockers, antispasmodics, antihistamines, antiallergics, cardiotonic agents, antiarrhythmics, diuretics, antihypertensives, vasopressors, antidepressants, antitussives, expectorants, thyroid hormones, sex hormones, antidiabetics, antitumor agents, antibiotics, chemotherapeutics and anesthetics, although this group is not exhaustive.

[0077] Lurasidone (3aR,4S,7R,7aS)-2-{[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methylene-2H-isoindole-1,3-dione or a pharmaceutically acceptable salt thereof, for example, (3aR,4S,7R,7aS)-2-{[(1R,2R)-2-[4-(1,2-Benzisothiazol-3-yl)-piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methylene-2H-isoindole-1,3-dione hydrochloride is a white to off-white powder.

[0078] The active substance is slightly soluble in water and belongs to BCS class II drug. Its poor oral bioavailability is mainly attributed to its extremely low solubility and dissolution rate (the absolute bioavailability in humans after a single oral administration is only 9%-19%).

[0079] The substrate layer also comprises at least one polyvinyl alcohol.

[0080] Polyvinyl alcohol (abbreviated as PVA or PVAL, sometimes also called PVOH) is a polymer with the following general structure

[0081]

[0082] It may also contain a small amount (about 2%) of the following types of structural units

[0083]

[0084] They belong to the class of vinyl polymers.

[0085] The commercially available polyvinyl alcohol is provided in the form of white-yellow powder or granules, generally with a degree of hydrolysis of 98 to 99 mol % or 87 to 89 mol %, that is, also containing residual contents of acetyl groups. The manufacturers characterize the polyvinyl alcohol by specifying the degree of polymerization or average molecular weight of the starting polymer, the degree of hydrolysis, the saponification value or the solution viscosity.

[0086] According to the invention, the at least one polyvinyl alcohol has an average molecular weight of 20,000 to 250,000 g / mol, in particular 20,000 to 40,000 g / mol.

[0087] The inventors have found that if the oral film comprises at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol, the average molecular weight of the polyvinyl alcohol can be adjusted within a wide range. However, if the average molecular weight is below 20,000 g / mol, the viscosity of the at least one polyvinyl alcohol becomes too low, which has a negative impact on the handling properties of the OTF during manufacture and application. If the average molecular weight is above 250,000 g / mol, the viscosity of the at least one polyvinyl alcohol becomes too high, which has a negative impact on the handling properties of the OTF, especially during manufacture. In addition, outside the scope of the claimed protection, the disintegration behavior of the oral film may be negatively affected.

[0088] In another embodiment of the present invention, at least one polyvinyl alcohol has a mean molecular weight of 20000 to 40000 g / mol or greater than 40000 to 250000 g / mol. Preferably, the mean molecular weight is 20000 to 40000 g / mol. In some embodiments, the mean molecular weight is 20000 to 210000 g / mol, and / or greater than 40000 to 210000 g / mol, and / or 20000 to 150000 g / mol, and / or greater than 40000 to 150000 g / mol, and / or 20000 to 100000 g / mol, and / or greater than 40000 to 100000 g / mol, and / or 20000 to 75000 g / mol, and / or greater than 40000 to 75000 g / mol in the scope of 75000 g / mol.

[0089] According to a preferred embodiment of the present invention, the average molecular weight of at least one polyvinyl alcohol is 20000 to 40000 g / mol. The average molecular weight in some embodiments refers to the number average molecular weight. The inventors have found that if at least one polyvinyl alcohol has an average molecular weight within the range, the OTF exhibits a desired balance of mechanical properties (especially foldability, tensile strength and puncture strength) and dissolution behavior.

[0090] In a preferred embodiment, the average molecular weight refers to the weight average molecular weight.

[0091] According to the present invention, polyvinyl alcohol with an average molecular weight of about 31,000 is particularly suitable. Polyvinyl alcohol with an average molecular weight of about 37,000 g / mol is also particularly suitable. Another specific example of polyvinyl alcohol suitable for the present invention is polyvinyl alcohol with an average molecular weight of about 205,000 g / mol.

[0092] Molecular weight can be determined, for example, by gel permeation chromatography.

[0093] In a preferred embodiment, the polyvinyl alcohol is partially hydrolyzed polyvinyl alcohol. For the purposes of the present invention, partially hydrolyzed polyvinyl alcohol refers to a polymer material derived from polyvinyl acetate in which a portion of the acetate groups have been hydrolyzed to form hydroxyl groups, resulting in, for example, a polymer having a degree of hydrolysis of 70% to 95%, preferably 80 to 92%, more preferably about 88%. The degree of hydrolysis is defined as the percentage of acetate groups that have been converted to hydroxyl groups.

[0094] In another embodiment, the polyvinyl alcohol is fully hydrolyzed polyvinyl alcohol, with a degree of hydrolysis greater than 95%, such as 97% or higher.

[0095] Furthermore, polyvinyl alcohols having a viscosity of 3.4 to 4.6 mPa in 40 g / l aqueous solution, determined by the “falling ball method” (Ph. Eur. 2.2.49), are particularly suitable.

[0096] Suitable polyvinyl alcohols are known under the name polyvinyl alcohol It has an average molecular weight of about 31,000 g / mol and a degree of hydrolysis of about 88%. Further specific examples include (average molecular weight about 37000 g / mol, degree of hydrolysis about 88%) and (Average molecular weight about 205000 g / mol, degree of hydrolysis about 88%).

[0097] In a preferred embodiment, at least one polyvinyl alcohol is provided in the substrate layer in an amount of 5 to 30 wt.%, preferably 10 to 25 wt.%, relative to the gross weight of the substrate layer. In another embodiment, at least one polyvinyl alcohol is provided in the substrate layer in an amount of 10 to 20 wt.%, preferably 15 to 25 wt.%, relative to the gross weight of the substrate layer. Therefore, in one embodiment, at least one polyvinyl alcohol is provided in the substrate layer in an amount of 5 wt.% to less than 10 wt.%, or 10 wt.% to 35 wt.%, or in an amount of 10 wt.% to less than 15 wt.%, or 15 wt.% to 25 wt.%, or greater than 25 wt.% to 30 wt.%, respectively relative to the gross weight of the substrate layer.

[0098] The matrix layer also comprises at least one polyvinyl alcohol-polyethylene glycol graft copolymer, also abbreviated as PVA-g-PEG.

[0099] Graft copolymers are branched polymers containing different monomer units in the main chain and in the side chains.

[0100] The term "graft copolymer" is a general term.

[0101] "Graft polymer" or "graft copolymer" refers to a type of polymer in which a main polymer backbone (also referred to as a graft copolymer backbone) has one or more side chains (also referred to as grafts) covalently attached thereto. These side chains are typically composed of one or more monomers different from the main polymer backbone and are attached to the backbone by chemical reactions such as free radical polymerization or polycondensation. The grafts may be attached to the backbone at random or specific locations and may vary in their molecular weight, composition, and structure.

[0102] The polyvinyl alcohol-polyethylene glycol graft copolymer provided herein preferably has a backbone comprising polyethylene glycol onto which polyvinyl alcohol units are grafted.

[0103] Preferably, the oral film according to the invention is further characterized in that at least one polyvinyl alcohol-polyethylene glycol graft copolymer has a polyethylene glycol backbone chain onto which polyvinyl alcohol units are grafted.

[0104] Preferably, the oral film according to the present invention is further characterized in that at least one polyvinyl alcohol-polyethylene glycol graft copolymer has a polyethylene glycol backbone chain onto which polyvinyl alcohol units are grafted, wherein the molar ratio of polyethylene glycol to polyvinyl alcohol is 1:3.

[0105] Preferably, the oral film according to the present invention is also characterized in that at least one polyvinyl alcohol-polyethylene glycol graft copolymer has a polyethylene glycol backbone chain to which polyvinyl alcohol units are grafted, wherein the average molecular weight of the polyvinyl alcohol-polyethylene glycol graft copolymer is in the range of 40,000 to 50,000 g / mol, preferably about 45,000 g / mol.

[0106] The average molecular weight refers in particular to the numerical value of the average molecular weight.

[0107] Most preferably, the average molecular weight refers to the weight average molecular weight.

[0108] Molecular weight can be determined, for example, by gel permeation chromatography.

[0109] A suitable and preferred polyvinyl alcohol-polyethylene glycol graft copolymer is known under the trade name Kollicoat IR (BASF).

[0110] The at least one polyvinyl alcohol-polyethylene glycol graft copolymer is preferably provided in the substrate layer in an amount of 5 to 35 wt.%, preferably 10 to 30 wt.%, relative to the total weight of the substrate layer. In another embodiment, the at least one polyvinyl alcohol-polyethylene glycol graft copolymer is provided in the substrate layer in an amount of 5 wt.% to less than 10 wt.% or 10 wt.% to 35 wt.%, preferably 10 wt.% to less than 15 wt.% or 10 wt.% to 25 wt.% or greater than 25 wt.% to 30 wt.%, each relative to the total weight of the substrate layer.

[0111] In a preferred embodiment, the oral film comprises the at least one polyvinyl alcohol-polyethylene glycol graft copolymer and the at least one polyvinyl alcohol in a combined amount of 25 wt.% to 65 wt.%, preferably 30 wt.% to 60 wt.%, more preferably 30 wt.% to 45 wt.%, relative to the total weight of the matrix layer.

[0112] The oral film according to the present invention preferably comprises a substantial amount of lurasidone or a pharmaceutically acceptable salt thereof.

[0113] Therefore, the oral film according to the present invention comprises a therapeutically effective amount of lurasidone.

[0114] When reference is made hereinafter to "lurasidone", it should be understood to refer to lurasidone in free form and in pharmaceutically acceptable salt form.

[0115] In one embodiment of the present invention, the oral film comprises 35 wt.% to 55 wt.%, preferably 35 wt.% to 53 wt.%, more preferably 40 wt.% to 45 wt.% of lurasidone or a pharmaceutically acceptable salt thereof in the matrix layer relative to the total weight of the matrix layer. As described above, it is particularly advantageous to have a high loading of lurasidone in the oral film to achieve a balance between the size and area weight of the OTF. However, if the amount of lurasidone becomes too high, the film may be too brittle to be adequately handled during manufacture and use.

[0116] The oral film may also contain 35 wt.% to 50 wt.% or more than 50 wt.% to 55 wt.%, preferably 35 wt.% to 50 wt.% or more than 50 wt.% to 53 wt.%, more preferably 40 wt.% to 45 wt.% of lurasidone or a pharmaceutically acceptable salt thereof, relative to the total weight of the matrix layer.

[0117] Therefore, preferably, the oral film of the present invention is characterized in that lurasidone or a pharmaceutically acceptable salt thereof is provided in the matrix layer in an amount of 35 to 50 wt.%, preferably 40 to 45 wt.%, relative to the total weight of the matrix layer.

[0118] The pharmaceutically acceptable salt of lurasidone may be selected from its halides (i.e., fluoride, chloride, bromide or iodide), sulfates, phosphates, bicarbonates, carbonates and / or carboxylates (e.g., acetate, citrate, lactate, tartrate, succinate, malate, fumarate or maleate).

[0119] A preferred pharmaceutically acceptable salt of lurasidone is lurasidone hydrochloride (lurasidone HCl).

[0120] The lurasidone in the matrix layer may be (completely) dissolved, or the matrix layer may contain lurasidone particles, preferably consisting of lurasidone hydrochloride, such that the lurasidone is present in dispersed form. Of course, if the lurasidone is present in dispersed form, the matrix layer may still contain lurasidone in dissolved form, depending on the solubility of the active substance in the matrix layer (e.g. saturated or supersaturated).

[0121] As long as the matrix layer remains in a dry state, at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol together provide sufficient cohesion for the matrix layer. In addition, these polymers are the main controlling factors for the disintegration behavior of the matrix layer. In particular, the matrix layer should disintegrate in a sufficiently long time to facilitate administration, but short enough to allow rapid release of the active substance into the oral cavity so that the OTF can be quickly swallowed and cannot be easily removed after administration.

[0122] In certain embodiments, this means that if the substrate layer is cast to have a thickness of 150 to 200 g / m 2 or 185 to 195 g / m 2 , for example about 190g / m 2 If the substrate layer is cast into a film with an area weight of 150 to 200 g / m2, the substrate layer dissolves in water, artificial or natural saliva or any other aqueous medium at 37°C and 50 rpm in less than 2 minutes, preferably less than 1.5 minutes, more preferably less than 1 minute, and most preferably less than 45 seconds. 2 or 185 to 195 g / m 2 , for example about 190g / m 2 The matrix layer can also be dissolved in water, artificial or natural saliva or any other aqueous medium at 37°C and 50 rpm in more than 5 seconds, preferably more than 10 seconds, and most preferably more than 15 seconds. It is worth noting that if the matrix layer is cast into an area weight of 150 to 200 g / m 2 or 185 to 195 g / m 2 , for example about 190g / m 2 If the film is made of a silicon-based film, the matrix layer can be dissolved in more than 5 seconds and less than 2 minutes, preferably more than 10 seconds and less than 1.5 minutes, more preferably more than 15 seconds and less than 1 minute, and most preferably more than 15 seconds and less than 45 seconds.

[0123] The oral film of the present invention may contain other components.

[0124] For example, the oral film may contain an additional polymer as a film former. Such film formers include polymers such as polyvinyl pyrrolidone (which may be 30F is commercially available from BASF), methylcellulose (can Commercially available from Colorcon), ethyl cellulose (can Commercially available from Colorcon), hydroxyethyl cellulose (can 250L commercially available from Ashland Industries), hydroxypropyl cellulose (can be Commercially available from Ashland Industries), hydroxypropyl methylcellulose (also known as hypromellose, which can be Commercially available from Shin-Etsu), sodium carboxymethylcellulose (the uncrosslinked sodium salt of carboxymethylcellulose, also known as CMC or carboxymethylcellulose, can be Commercially available from Ashland Industries), maltodextrin, polyethylene glycol-polyvinyl acetate and polyvinyl caprolactam-based graft copolymers (available from Commercially available from BASF), polyvinylpyrrolidone-polyvinyl acetate copolymer (also known as copovidone and available, for example, as VA64 is commercially available from BASF), polyethylene oxide, polyethylene glycol, methacrylic acid-methyl methacrylate copolymer (can be and Commercially available from Evonik) and methacrylic acid-ethyl methacrylate copolymer (available from and Commercially available from Evonik), as well as natural film formers such as shellac, pectin, gelatin, alginates, pullulan and starch derivatives, and any mixtures thereof.

[0125] Preferably, such film formers are present in the matrix layer in an amount of at most 10 wt.%, preferably at most 5 wt.%. In view of the undesirable tactile properties of cellulose and in particular the mouthfeel, the film former is preferably not selected from cellulose and cellulose derivatives (i.e., for example methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose). Therefore, in a preferred embodiment, the matrix layer does not contain cellulose and does not contain cellulose derivatives.

[0126] In a particularly preferred embodiment, the matrix layer comprises no film formers other than at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol.

[0127] The matrix layer of the OTF according to the present invention may contain additional excipients or additives selected from fatty acids, sweeteners, flavoring agents ("flavorings"), colorants ("coloring agents"), solubilizers, plasticizers, disintegrants, emulsifiers, stabilizers and buffering agents.

[0128] Such excipients or additives may be present in the matrix layer in an amount of 0.001 to 15 wt.% of the matrix layer for each additive. In one embodiment, the total amount of all additives is 0.001 to 25 wt.% of the matrix layer. Hereinafter, when a range of the amount of a particular additive is given, this range refers to the amount of each individual additive.

[0129] It should be noted that in pharmaceutical preparations, formulation components are classified according to their physicochemical and physiological properties and according to their functions. This means in particular that it is not excluded that a substance or compound belonging to a type belongs to another formulation component type. For example, a certain polymer may be a crystallization inhibitor, but still a tackifier. Some substances may be, for example, typical softeners, but simultaneously act as penetration enhancers. Those skilled in the art can determine one or more formulation component types to which a certain substance or compound belongs based on his common sense. In the following, details about excipients and additives are provided, however, the details should not be understood to be exclusive. Other substances not clearly listed in this specification may also be used according to the present invention, and in the sense of the present invention, it is not excluded that substances and / or compounds clearly listed for a formulation component type are used as another formulation component.

[0130] The fatty acid may be in particular a saturated or unsaturated straight or branched carboxylic acid containing 4 to 24 carbon atoms, and may in particular be selected from the group consisting of caprylic acid, myristoleic acid, palmitoleic acid, cis-6-hexadecenoic acid, oleic acid, elaidic acid, vaccenic acid, linoleic acid, linoelaidic acid, alpha-linolenic acid, arachidonic acid, eicosapentaenoic acid, erucic acid and docosahexaenoic acid. Particularly preferred are oleic acid or linoleic acid.

[0131] It is generally known in the art that the active substance-containing layer of the oral film may contain a permeation enhancer. Typical permeation enhancers include those selected from diethylene glycol monoethyl ether (transcutol), dipropylene glycol, levulinic acid, 2,5-dimethyl isosorbide (dottisol), lauryl lactate, lactic acid, dimethylethylene urea, N,N-diethyl-m-toluamide (DEET), propylene glycol monooctanoate, 2-methoxy-4-(prop-2-en-1-yl)phenol, laurocapram, bile acid, bile acid salts, bile acid derivatives, acylcarnitines, sodium lauryl sulfate, dimethyl sulfoxide, sodium lauryl sulfate, terpenes, cyclodextrins, cyclodextrin derivatives, saponins, saponin derivatives, chitosan, EDTA, citric acid and salicylates. From the point of view that the oral film of the present invention is intended to deliver lurasidone orally to the gastrointestinal tract, the matrix layer according to the present invention preferably does not contain a permeation enhancer, in particular does not contain a permeation enhancer selected from this list.

[0132] The matrix layer according to the present invention may include a pH regulator. Preferably, the pH regulator is selected from monoacids and polytropic acids, monovalent bases, divalent bases and trivalent bases, buffer solutions of mixtures of weak acids and their conjugate bases, amine derivatives, inorganic base derivatives, polymers having basic and acidic functional groups, respectively.

[0133] Preferably, the oral film according to the invention is further characterized in that at least one polyvinyl alcohol is provided in the matrix layer in an amount of 5 to 20 wt.%, preferably 10 to 15 wt.%, relative to the total weight of the matrix layer.

[0134] Preferably, the oral film according to the invention is further characterized in that at least one polyvinyl alcohol-polyethylene glycol graft copolymer is provided in the matrix layer in an amount of 10 to 35 wt.%, preferably 15 to 25 wt.%, relative to the total weight of the matrix layer.

[0135] The amounts of polyvinyl alcohol and polyvinyl alcohol-polyethylene glycol graft copolymers disclosed herein are particularly suitable because they ensure that the oral film can be loaded with a large amount of active agent while maintaining a flexible film that exhibits a pleasant feel in the patient's mouth.

[0136] Preferably, the oral film according to the present invention does not contain any other polymers besides polyvinyl alcohol and polyvinyl alcohol-polyethylene glycol graft copolymer.

[0137] In particular, the oral film according to the present invention does not contain any cellulose based polymers such as HPMC.

[0138] Preferably, the oral film according to the invention is further characterized in that the matrix layer comprises at least one plasticizer.

[0139] The plasticizer is in particular selected from monosaccharides, disaccharides, oligosaccharides and polysaccharides and derivatives thereof, such as sorbitol, glycerol, polyethylene glycol, triacetin, triethyl citrate, propylene glycol and medium chain triglycerides.

[0140] Preferred plasticizers are selected from triacetin, PEG400 and / or glycerol. Particularly preferred is triacetin (also known as glycerin triacetate or 1,2,3-triacetoxypropane). It was found that the plasticizers, especially triacetin, provide the best results with regard to tactile feel and OTF flexibility.

[0141] Based on the gross weight of substrate layer, at least one plasticizer is preferably present in the substrate layer in an amount of 1 to 15 wt.%, preferably 4 to 10 wt.%, most preferably 5 to 10 wt.%. At least one plasticizer can also be present in the substrate layer in an amount of 1 to 10 wt.% or greater than 10 to 15 wt.%, or in an amount of 4 to less than 5 wt.% or 5 to 10 wt.%, each relative to the gross weight of the substrate layer.

[0142] Furthermore, at least one plasticizer is preferably present in the substrate layer in an amount of 1 to 10%, preferably 5 to 10%, relative to the total weight of the substrate layer.

[0143] Preferably, the oral film according to the invention is further characterized in that the matrix layer comprises at least one emulsifier.

[0144] Examples of emulsifiers which can be used are soaps, metal soaps, organic soaps such as ethanolamino oleate or stearate, sulphurized compounds such as sodium lauryl sulphate, quaternary ammonium compounds, fatty alcohols such as lauryl alcohol, cetyl alcohol, stearyl alcohol or palmityl alcohol, partial fatty acid esters of polyols with saturated fatty acids such as glyceryl monostearate, pentaerythritol monostearate, ethylene glycol monostearate, propylene glycol monostearate, partial fatty acid esters of polyols with unsaturated fatty acids such as glyceryl monooleate, glyceryl dioleate, pentaerythritol monooleate, polyoxyethylene esters of further fatty acids such as polyoxyethylene stearate, polymerization products of ethylene oxide and propylene oxide with fatty alcohols such as fatty alcohol polyethylene glycol ethers, or polymerization products of ethylene oxide and propylene oxide with fatty acids such as fatty acid ethoxylates, polysorbates, sorbitan esters, macrogolglycerol hydroxystearate, lecithin, mono- or diglycerides and / or polyoxyethylene fatty acid ethers.

[0145] Other emulsifiers that may be used include lecithin, polysorbates, sorbitan esters such as polyoxyethylene (20) sorbitan monooleate, polyoxyethylene (23) sorbitan monolaurate, polyoxyethylene fatty acid ethers such as polyoxyethylene (23) lauryl ether or polyoxyethylene (2) stearyl alcohol, polyethylene glycol glyceryl hydroxystearate, glyceryl monooleate and glyceryl dioleate and / or mixtures thereof, for example polysorbate 80 or 60, Span 83 or 85, Kolliphor RH40, Tween 20, Tween 80, Atmos 300, Brij S2 and Brij L-23 sold under the trade names.

[0146] Additional examples include ethoxylated sorbitans esterified with fatty acids, such as polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monostearate, and polyoxyethylene sorbitan monooleate (commercially available as Tween 80 or polysorbate 80), safflower oleosomes, propylene glycol, polyethoxylated castor oil, soy lecithin, sodium phosphate, mono- and diglycerides of fatty acids, sodium stearoyl lactylate, diacetyl tartaric acid esters of mono- and diglycerides, and polyethoxylated hydrogenated castor oil (commercially available as Cremophor RH 40 from BASF).

[0147] Preferred emulsifiers are selected from polysorbate 80, polysorbate 60, diacetyl esters of mono- and diglycerides, especially polysorbate 80.

[0148] Among other functions, emulsifiers improve the dispersion of lurasidone particles in the polymer matrix. This function becomes particularly important if the OTF contains higher amounts of flavoring agents, which unexpectedly change the surface tension of the coating composition, resulting in the appearance of holes in the coated film. However, as mentioned above, the presence of flavoring agents is preferred in view of the bitter taste of lurasidone. Therefore, the inventors have recognized that emulsifiers help to incorporate larger amounts of flavoring agents into the matrix layer, thereby helping to improve patient compliance.

[0149] Furthermore, at least one emulsifier is preferably present in the matrix layer in an amount of 0.1 to 2 wt.%, preferably 0.5 to 1.5 wt.%, relative to the total weight of the matrix layer.

[0150] The oral film according to the invention is also preferably characterized in that the matrix layer further comprises at least one auxiliary substance selected from colorants, flavoring agents and / or sweeteners.

[0151] Each of these auxiliary substances is preferably contained in an amount of 0.005 to 15 wt.%, preferably 0.1 to 10 wt.% or 0.1 to 5 wt.%, in each case relative to the total weight of the matrix layer.

[0152] The colorant that may be optionally incorporated into the matrix layer must be safe in terms of toxicity and should be approved by the US Food and Drug Administration (FDA).

[0153] Any colorant suitable for use in pharmaceutical / food applications may be included, particularly those licensed for use by the U.S. FDA or by the European agencies EFSA / EMA or the China National Drug Administration. The colorant may, for example, be selected from the group consisting of titanium dioxide, brilliant blue FCF, indigo carmine, fast green FCF, erythrosine, allura red AC, tartrate and sunset yellow FCF, curcumin, riboflavin, riboflavin-5'-phosphate, quinoline yellow, orange yellow S, carmine, carminic acid, azorubin, carmoisine, amaranth, erythrosine, Ponceau 4R, carmine A, patent blue V, indigo, chlorophyll, chlorophyllin , copper complex of chlorophyll and chlorophyllin, green S, ordinary caramel, caustic sulfite caramel, ammonia caramel, ammonium sulfite caramel, brilliant black BN, black PN, vegetable carbon black, brown HT, carotene, bixin, norbixin, pepper extract, capsanthin, capsanthin, lycopene, β-apo-8'-carotenal, lutein, canthaxanthin, beetroot red, betanin, anthocyanin, calcium carbonate, iron oxides and hydroxides, aluminum, silver, gold and Lithol Rubine BK.

[0154] Lurasidone has an unpleasant bitter taste which should be masked to improve patient compliance. Therefore, in a preferred embodiment, the matrix layer further comprises one or more excipients selected from sweeteners and flavoring agents.

[0155] Useable flavoring agents include those known to those skilled in the art, such as natural flavoring agents and artificial flavoring agents. These flavoring agents can be selected from synthetic flavoring oils and flavoring aromatics, and / or oils, oleoresins and extracts derived from plants, leaves, flowers, fruits, etc., and combinations thereof. Representative flavoring oils include: spearmint oil, cinnamon oil, peppermint oil, clove oil, bay oil, thyme oil, cedar leaf oil, nutmeg oil, sage oil and bitter almond oil. Artificial, natural or synthetic fruit flavoring agents, such as vanilla extract, chocolate, coffee, cocoa and citrus oil, include lemon, orange, grape, lime and grapefruit, and fruit essence, including apple, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot, etc., are also useful. These flavoring agents can be used alone or in combination. Commonly used flavoring agents include mint such as peppermint, artificial vanilla extract, cinnamon derivatives and various fruit flavoring agents, whether used alone or in combination. Flavoring agents such as aldehydes and esters may also be used, including cinnamyl cinnamaldehyde, citral, diethyl acetal, dihydrocarvyl eugenyl formate, p-methylanisole, etc. Generally, any flavoring agent or food additive may be used, such as those described in Chemicals Used in Food Processing, Publication No. 1274 of the National Academy of Sciences, pp. 63-258. Other examples of aldehyde flavoring agents include, but are not limited to, acetaldehyde (apple); benzaldehyde (cherry, almond); cinnamaldehyde (cinnamon); citral, i.e., alpha citral (lemon, lime); neral, i.e., beta citral (lemon, lime); decanal (orange, lemon); ethyl vanillin (vanilla, cream); heliotropin, i.e., piperonal (vanilla, cream); vanillic aldehyde (vanilla, cream); alpha-amyl cinnamaldehyde (spicy fruit flavoring); butyraldehyde (butter, cheese); valeraldehyde (butter, cheese); citronellal (modifier (modif ies), various types); decanal (citrus fruits); aldehyde C-8 (citrus fruits); aldehyde C-9 (citrus fruits); aldehyde C-12 (citrus fruits); 2-ethylbutyraldehyde (berry fruits); hexenal, i.e., trans-2 (berry fruits); tolualdehyde (cherries, almonds); veratraldehyde (vanilla); 2,6-dimethyl-5-heptenal, i.e., melonal (melon); 2-6-dimethyloctanal (green fruits); and 2-dodecenal (citrus, tangerines); cherries; grapes; mixtures thereof; etc.

[0156] In a further preferred embodiment, the matrix layer comprises one or more natural or artificial flavoring agents selected from the group consisting of: vanillin, methyl salicylate, menthol, manzanate, diacetyl, acetoin, isoamyl acetate, benzaldehyde, cinnamaldehyde, cherry flavoring, ethyl propionate, methyl anthranilate, limonene, ethyl decadienoate, allyl hexanoate, ethyl maltol, 2,4-dithiapentane, ethyl vanillin and eucalyptol and flavoring compositions such as peppermint flavoring. Cherry flavoring is particularly preferred.

[0157] Sweeteners that may be included are those well known in the art, including natural sweeteners and artificial sweeteners. Suitable sweeteners include, for example, carbohydrates, monosaccharides, disaccharides, oligosaccharides, sucralose, aspartame, sodium cyclamate, saccharin, neohesperidin, thaumatin, stevioside, acesulfame potassium and salts thereof.

[0158] Maltose, lactose, sucrose, dextrose (glucose) and trehalose, and sugar alcohols such as mannitol, sorbitol, xylitol, maltitol, etc. Examples of other carbohydrates are maltodextrin, corn syrup (from corn), soluble starches.

[0159] Other exemplary sweeteners include glycyrrhizin, aspartame, saccharin, steviol glycosides, naringin dihydrochalcone, aspartame acesulfame potassium salt, sucralose, monellin, thaumatin, neohesperidin dihydrochalcone, and neotame.

[0160] In certain preferred embodiments, the matrix layer comprises one or more natural or artificial sweeteners selected from sucrose, glucose, fructose, sorbitol, mannitol, isomalt, maltitol, lactitol, xylitol, erythritol, sucralose, acesulfame potassium, aspartame, sodium cyclamate, neohesperidin, neotame, steviol glycosides, thaumatin and saccharin sodium. Particularly preferably, the matrix layer comprises one or more natural or artificial sweeteners selected from sorbitol, sucralose and neotame. Sugar alcohols, such as sorbitol, can simultaneously serve as a humectant.

[0161] Sorbitol, sucralose and / or neotame are preferred.

[0162] The oral film according to the present invention may further and / or additionally comprise at least one auxiliary substance selected from taste masking agents, enhancers, pH regulators, wetting agents, preservatives and / or antioxidants.

[0163] Each of these auxiliary substances is preferably contained in an amount of 0.005 to 15 wt.%, preferably 0.1 to 10 wt.% or 0.1 to 5 wt.%, in each case relative to the total weight of the matrix layer.

[0164] According to the matrix layer of the present invention, wetting agent can be included.Wetting agent is the material used in the preparation, helps to keep moisture by attracting and keeping the water molecules of the surrounding environment.Wetting agent can be selected from sugar alcohol, glycerol, propylene glycol, sorbitol, urea, hyaluronic acid, lactic acid, panthenol (provitamin b5), sodium lactate, honey, aloe gel, butylene glycol, xylitol, erythritol, maltitol, mannitol, isomalt, lactitol, hydrogenated starch hydrolysate (HSH), dulcitol (dulcitol), ribitol, arabitol and threitol, and preferred wetting agent is sorbitol.Sorbitol can serve as sweetener simultaneously.

[0165] The inventors have found that wetting agents can help increase the polarity of oral films, thereby facilitating disintegration. Therefore, the matrix layer may further comprise a wetting agent in an amount of 2 to 10 wt.%, preferably 5 to 10 wt.%, wherein the wetting agent is preferably a sugar alcohol such as sorbitol. One embodiment of the present invention relates to an oral film comprising a matrix layer, wherein the matrix layer comprises lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol having an average molecular weight of 20,000 to 40,000 g / mol or greater than 40,000 to 250,000 g / mol, provided that if a polyvinyl alcohol having an average molecular weight greater than 40,000 to 250,000 g / mol is used, the matrix layer of the oral film further comprises 2 to 10 wt.%, preferably 5 to 10 wt.% of a wetting agent, wherein the wetting agent is preferably a sugar alcohol such as sorbitol.

[0166] In addition, the matrix layer of the present invention may contain residual process solvents, such as water. The residual process solvents are preferably contained in the matrix layer in an amount of less than 10 wt.%, preferably less than 5 wt.%.

[0167] The oral film according to the invention is particularly preferably characterized in that lurasidone or a pharmaceutically acceptable salt thereof is present in the form of microparticles, in particular D 90 The particle size is 1 to 100 μm, or 3 to 20 μm, preferably 1 to 10 μm. 90 It can be 1 to 20 or more than 20 to 100 μm, or D 90 It is 3 to 20 μm or more than 20 to 100 μm, preferably 1 to 10 μm.

[0168] Preferably, the oral film according to the present invention is further characterized in that lurasidone or a pharmaceutically acceptable salt thereof is present in the form of microparticles, in particular in the form of D 90 The nanoparticles are in the form of microparticles with a size of 1 to 20 μm, or 3 to 20 μm, preferably 1 to 10 μm.

[0169] Additionally or alternatively, the D 50It may be in the range of 0.1 to 25 μm, preferably 0.5 to 5 μm.

[0170] Particle size refers to the volume weighted particle size D 90 (i.e., 90% of all particles by volume have a particle size smaller than the stated value) and volume median particle size D 50 (ie 50% by volume of all particles have a particle size smaller than the stated value), and can be determined, for example, by laser diffraction analysis or sieve analysis, in particular laser diffraction analysis.

[0171] Preferably, lurasidone or a pharmaceutically acceptable salt thereof is present in an amount of 90 It exists in the form of particles smaller than 5 μm.

[0172] Since the active ingredient is preferably present in an undissolved state, ie in suspension, the active ingredient is preferably present in a sufficiently small particle size. Particles that are too large can lead to streaks in the final film and also produce a rough, uneven film surface.

[0173] Therefore, the particle size of the micronized particles may contribute to the beneficial tactile properties of OTF and the dissolution behavior in the gastrointestinal tract.

[0174] Preferably, the oral film according to the present invention is further characterized in that lurasidone or a pharmaceutically acceptable salt thereof is substantially insoluble in the matrix layer.

[0175] Substantially insoluble means that more than 95%, preferably more than 98% by weight of lurasidone or a pharmaceutically acceptable salt thereof is rendered insoluble.

[0176] Preferably, the oral film according to the present invention is also characterized in that the area density (also called area weight) of the oral film is preferably at least 10 g / m 2 , more preferably at least 20 g / m 2 or at least 30g / m 2 , most preferably 50g / m 2 , or less than or equal to 400g / m 2 , more preferably less than or equal to 350g / m 2 , or less than or equal to 300g / m 2 , or most preferably less than 250g / m 2 .

[0177] Preferably, the area density of the oral film is 50 to 300 g / m 2 , preferably 150 to 250 g / m 2 .

[0178] The area density is selected so that the OTF can be easily handled and administered and disintegrates within the desired time frame. In particular, OTFs with lower area density are thinner and disintegrate faster, which is preferred, but are also more brittle. Therefore, the area density of the oral film can also be 80 to 150 g / m 2 .

[0179] In one embodiment, the oral film according to the invention is also characterized in that it contains a total amount of 15-55 mg, preferably 25-55 mg, such as about 20 mg or about 40 mg of lurasidone in the form of lurasidone hydrochloride. Therefore, the oral film according to the invention can contain a total amount of 15 to less than 25 mg or 25 to 55 mg of lurasidone hydrochloride.

[0180] Preferably, the oral film according to the present invention is further characterized in that lurasidone or a pharmaceutically acceptable salt thereof comprises a total amount of 25 to 55 mg, preferably about 20 mg or about 40 mg of lurasidone hydrochloride.

[0181] Therefore, in a preferred embodiment, the OTF comprises lurasidone or a pharmaceutically acceptable salt thereof in an amount of 35 to 55 wt.%, preferably 35 to 53 wt.%, relative to the total weight of the matrix layer, and the area density of the oral film is 50 to 300 g / m 2 , preferably 80 to 150 g / m 2 or 150 to 250 g / m 2 .

[0182] The preferred amount and area weight of lurasidone in the matrix layer is selected so that the size of a single dose of OTF is 2-6 cm 2 The lurasidone OTF of the range comprises a total amount of 25-55 mg of lurasidone hydrochloride. Particularly preferably, the amount and area weight of lurasidone in the matrix layer are selected so that the size of the OTF of a single dose is 2.5 cm 2 The lurasidone OTF contains a total amount of about 20 mg of lurasidone hydrochloride and a single-dose OTF size of 5 cm 2 The lurasidone OTF contains a total amount of about 40 mg of lurasidone hydrochloride.

[0183] Preferably, the oral film according to the present invention is further characterized in that at least 70% or at least 80% of lurasidone or a pharmaceutically acceptable salt thereof is released within the first 15 minutes after administration at a pH of 3.8 (simulating the pH value present in the gastrointestinal tract, the absorption site of lurasidone).

[0184] The oral film is also preferably characterized in that at least 70% or at least 80%, preferably at least 90% of lurasidone or a pharmaceutically acceptable salt thereof is released within the first 15 minutes after immersion in an aqueous solution with a pH of 3.8 at a temperature of 37±0.5°C. The aqueous solution with a pH of 3.8 may be a mixture of a disodium hydrogen phosphate buffer and a citric acid buffer, more preferably a McIlvaine buffer ([(0.025M citric acid solution+0.05M Na2HPO4 solution (3:2)]). The pH value may be selected to simulate the pH value present in the gastrointestinal tract in a fed state.

[0185] Additionally or alternatively, the oral film is characterized by releasing at least 70% or at least 80%, preferably at least 90% of lurasidone or a pharmaceutically acceptable salt thereof within the first 15 minutes after immersion in an aqueous solution having a pH of 1.2 at a temperature of 37±0.5°C. The aqueous solution having a pH of 1.2 may be a dilute hydrochloric acid solution. The pH may be selected to simulate the pH present in the gastrointestinal tract in a fed state.

[0186] Additionally or alternatively, the oral film is characterized by releasing up to 70% or up to 60% of lurasidone or a pharmaceutically acceptable salt thereof within the first 15 minutes after immersion in an aqueous solution having a pH of 4.5 at a temperature of 37±0.5° C. The aqueous solution having a pH of 4.5 may be a mixture of a disodium hydrogen phosphate buffer and a citric acid buffer.

[0187] Additionally or alternatively, the oral film is characterized by releasing up to 15% or up to 10% of lurasidone or a pharmaceutically acceptable salt thereof within the first 15 minutes after immersion in an aqueous solution having a pH of 6.8 at a temperature of 37±0.5°C. The aqueous solution having a pH of 6.8 may be a mixture of disodium hydrogen phosphate buffer and citric acid. The pH may be selected to simulate conditions in the oral cavity.

[0188] The release profile ensures that lurasidone dissolves in the gastrointestinal tract but does not dissolve prematurely during administration (eg, in saliva).

[0189] Within the meaning of the present invention, "release" of lurasidone refers to the portion of the total amount of lurasidone present in the OTF that is dissolved in aqueous solution in a USP dissolution apparatus II with an additional settler to immobilize the OTF on the bottom of the container.

[0190] Preferably, by dividing the size into 5cm 2 The OTF of is placed in 900 mL of aqueous solution in USP dissolution apparatus II and the release is measured at a stirring speed of 50 rpm. Preferably, the aqueous solution is degassed before use.

[0191] Most preferably, the release of lurasidone is measured according to FDA dissolution methods and parameters.

[0192] For the purposes of the present invention, OTF is considered bioequivalent to Latuda if the dissolution profiles are substantially matched. More specifically, OTF is considered bioequivalent if at least 80% of lurasidone or a pharmaceutically acceptable salt thereof is released within the first 15 minutes after immersion in an aqueous solution at a temperature of 37±0.5°C and having a pH of 1.2 and / or if at least 90% of lurasidone or a pharmaceutically acceptable salt thereof is released within the first 15 minutes after immersion in an aqueous solution at a temperature of 37±0.5°C and having a pH of 3.8 and having a temperature of 37±0.5°C.

[0193] In another preferred embodiment, the oral film of the present invention has a tensile strength of at least 1 N, or at least 2 N, preferably at least 5 N. Preferably, the oral film of the present invention has a tensile strength of 1-15 N, preferably 2-12 N, more preferably 5-12 N, and most preferably 6-12 N. The tensile strength can be determined using a tensile strength tester. In this method, a single unit of the test product is fixed with two clamp jaws spaced 10 mm apart from each other. When the sample is fixed, the upper clamp jaw moves upward at a speed of 300 mm / min over a measuring path of 10 mm. The maximum force required to tear a single unit is determined in Newtons (N).

[0194] Tensile strength is therefore a measure of the maximum tensile (stretching or pulling) stress that a material can withstand before breaking or failing. It is therefore a measure of the durability and mechanical integrity of the OTF. During manufacturing, packaging, storage and handling, the OTF is subjected to a variety of mechanical stresses. A sufficiently high tensile strength ensures that the film does not tear or break easily, maintaining its structural integrity during these processes. In addition, films with sufficient tensile strength are easier to handle without premature mechanical disintegration. For this reason, high tensile strength can even contribute to better patient compliance by making the film stronger and easier to handle without worrying about breaking.

[0195] Preferably, the oral film of the present invention will not break or crumble when folded. This property is preferably evaluated by folding a single unit located in a pouch, rolling up a standard 2 kg tube on the folded edge and determining whether the sample remains in one piece or breaks into two parts. Similar to tensile strength, good resistance to fracture or chipping ensures that the film will not break or crumble when produced, removed from the package or placed in the mouth. Therefore, they are easier to manufacture, handle and administer, which enhances the user experience and compliance.

[0196] In a further preferred embodiment, the puncture strength of the oral film of the present invention is 0.02 to 0.2 N / mm 2 , preferably 0.03 to 0.15 N / mm 2 , more preferably 0.03 to 0.1 N / mm2 Puncture strength can be determined using standard equipment (e.g., a force measuring device that measures the maximum force applied to the OTF until the OTF breaks or is punctured). Puncture strength refers to the ability of a material to resist penetration by a sharp object. It measures how much force is required to puncture the material. Similar to tensile strength, a sufficiently high puncture strength indicates good mechanical stability of the OTF. For example, the OTF is not easily punctured by a finger or damaged by a sharp object during handling, and is also not easily damaged by a sharp object during the manufacturing process.

[0197] The oral film according to the present invention is not subject to any limitation in terms of structure.

[0198] Thus, the oral film according to the present invention may be provided in the form of a single-layer oral film and may therefore consist only of the matrix layer defined above.

[0199] Thus, in another embodiment, the oral film according to the invention may be provided in the form of a multilayer oral film and may therefore contain further layers in addition to the matrix layer defined above.

[0200] Each of the plurality of layers provided, in particular the matrix layer, preferably has in each case a layer thickness of preferably 10 μm to 500 μm, particularly preferably 20 μm to 300 μm.

[0201] If the individual layers, in particular the matrix layer, are present in the form of cured foams, each of the plurality of layers provided as foams preferably has a layer thickness of preferably 10 μm to 3000 μm, particularly preferably 90 μm to 2000 μm.

[0202] The multiple layers may be laminated directly onto each other, or may be connected to an adhesive layer disposed in between.

[0203] The additional layer may be selected from a backing layer, a decorative layer, an adhesive layer, a mucosal contact layer, a mucoadhesive layer, a protective layer, a water-soluble adhesive layer, a buffer layer and / or an additional active ingredient layer.

[0204] However, in a particularly preferred embodiment, the oral film consists of a matrix layer.

[0205] Preferably, the oral film does not include a backing layer. As mentioned above, the backing layer in the sense of the present invention is any layer in the oral film that can prevent the premature dissolution of the active substance contained in the oral film. Therefore, in a specific embodiment, the time required for the backing layer to dissolve is at least as long as the time required for (a large amount of) active substances to be delivered through the mucosa, for example, as long as the time required for the matrix layer to dissolve. Therefore, in certain embodiments, after applying the oral film to human patients, the backing layer is insoluble in less than 2 minutes, less than 1 minute or less than 45 seconds. In some embodiments, the backing layer is incompletely dissolved in water, artificial or natural saliva or any other aqueous medium at 37°C and 50rpm in less than 4 minutes, less than 2 minutes or less than 1 minute.

[0206] Within the meaning of the present invention, the term "mucoadhesive" refers in particular to a material which is able to adhere to and come into contact with a mucosa, but which is preferably non-adhesive and can be touched and handled with the fingers in a dry state, for example by applying it in the oral cavity, without accidentally adhering to the skin of the fingers. When in contact with the mucosa, the mucoadhesive layer is "self-adhesive", i.e. provides adhesion to the mucosa such that generally no further fixing aids are required. The adhesion strength is preferably strong enough that typical movements in the oral cavity are not sufficient to displace the mucoadhesive layer adhered to the mucosa. A "mucoadhesive" layer structure comprises a mucoadhesive layer for mucosal contact, which can be provided in the form of a mucoadhesive matrix layer or in the form of an additional layer, i.e. a mucoadhesive mucosal contact layer. A mucoadhesive cover layer can still be used to promote adhesion.

[0207] Within the meaning of the present invention, the term "mucosal contact layer" refers to a layer included in the oral film that is in direct contact with the patient's mucosa during administration. When the oral film comprises a mucosal contact layer, the other layers do not contact the mucosa and do not necessarily have mucoadhesive properties. The release area is provided by the area of ​​the matrix layer. The mucosal contact layer can be used to enhance adhesion. The dimensions of the additional mucosal contact layer and the matrix layer are generally coextensive and correspond to the release area. Preferably, the oral film of the present invention does not comprise a mucosal contact layer, a mucoadhesive cover layer or a mucoadhesive matrix layer.

[0208] As mentioned above, the oral film may also include a decorative layer. In another embodiment, the oral film does not include a decorative layer.

[0209] In contrast to the mucosal contact layer, the decorative layer is located on top of the matrix layer. The decorative layer can provide decorative means, such as coloring or imprinting, or can simply prevent the patient from contacting the matrix layer during oral thin film administration. For this protective function, it is preferred that the decorative layer completely covers the matrix layer. Therefore, in certain embodiments, the OTF also includes a decorative layer, and the size of the matrix layer and the size of the decorative layer are coextensive, or the size of the decorative layer is greater than the surface area of ​​the matrix layer and extends the surface area of ​​the matrix layer.

[0210] On the other hand, the decorative layer should not be confused with the backing layer. This is not the function of the decorative layer, and indeed it would be undesirable if the decorative layer created an obstacle to the release of the active substance into the saliva. Therefore, the decorative layer dissolves quickly enough not to hinder the dispersion of the active substance into the saliva, and in certain embodiments, the decorative layer dissolves in water, artificial or natural saliva or any other aqueous medium at 37° C. and 150 rpm in less than 2 minutes, less than 1 minute or less than 30 seconds.

[0211] However, in terms of ease of manufacture and simplicity, an elegant solution for the oral film is that the matrix layer is the oral film itself. In other words, in certain preferred embodiments, the oral film of the present invention comprises neither a mucosal contact layer nor a decorative layer, and in particular, the oral film can simply consist of the matrix layer.

[0212] As defined in DIN EN 923:2016-03, an adhesive layer is understood to mean a layer which can be used as an adhesive. Thus, a non-adhesive layer cannot be used as an adhesive as defined above.

[0213] In particular, the water-soluble adhesive layers described in DE 10 2017 127 452 A1 are suitable as adhesive layers, the content of which in this respect is expressly incorporated in its entirety into the present disclosure.

[0214] For example, a buffer layer for setting the pH value or a slowly dissolving or insoluble layer to protect the oral film from premature erosion may be provided as a further layer.

[0215] Alternatively, further matrix layers may be provided containing other pharmaceutically active agents or flavouring or taste-masking agents.

[0216] In one embodiment, the oral thin film according to the invention is characterized in that the matrix layer is in the form of a smooth film. This means that the matrix layer is not provided in the form of a foam, for example.

[0217] The matrix layer can be in the form of a smooth film (i.e., a monolithic film), or can be in the form of a foam film. Preferably, the matrix layer is in the form of a smooth film (i.e., a monolithic film). Therefore, it is preferred that the matrix layer is not present in the oral film in the form of a foam film. The terms "monolithic film" and "smooth film" are used interchangeably in this article. The terms "foam" and "foam film" are also used interchangeably in this article.

[0218] The smooth film is preferably characterized in that the smooth film has a volume fraction of bubbles or cavities of 0% to 25% relative to the total volume of the substrate layer. These cavities are usually formed during the process of preparing the smooth film and should be avoided to the greatest extent possible when a smooth film is desired.

[0219] In another embodiment, the oral film according to the invention is characterized in that the matrix layer is in the form of a solidified foam having cavities.

[0220] The chambers can be separated from one another and are preferably provided in the form of bubbles, wherein the chambers are filled with air or a gas, preferably with an inert gas, particularly preferably with nitrogen, carbon dioxide, helium or a mixture of at least two of these gases.

[0221] According to another embodiment, it is provided that the cavities are connected to one another, preferably by forming a system of connecting channels penetrating the matrix.

[0222] The cavity preferably has a volume fraction of 25% to 98%, preferably 50% to 80%, relative to the total volume of the matrix layer. In this way, the beneficial effect of accelerating the disintegration and / or dissolution of the matrix layer is advantageously effected.

[0223] In particular, the lumen and the associated larger surface of the membrane facilitates the penetration of water or saliva or other body fluids into the interior of the dosage form and thus accelerates the disintegration and / or dissolution of the dosage form and the release of the active agent.

[0224] On the other hand, the wall thickness of the cavities is preferably small, since these represent, for example, solidified gas bubbles and these cavities therefore dissolve or collapse quickly.

[0225] Another advantage of this embodiment is that, due to the formulation being a foam, despite the relatively high area density, it can provide faster drying than a comparable non-foaming composition.

[0226] Furthermore, in order to improve the stability of the foam before or after drying, a surface-active substance or a surfactant may be added to the base layer for forming the foam or to the obtained foam before or after drying.

[0227] Another parameter that influences the properties of the dosage form according to the invention is the diameter of the cavities or gas bubbles. The gas bubbles or cavities are preferably produced with the aid of a foaming machine, with which the diameter of the gas bubbles can be set almost arbitrarily within a wide range. Thus, the diameter of the gas bubbles or cavities can be in the range of 0.01 to 350 μm. The diameter is particularly preferably in the range of 10 to 200 μm.

[0228] The oral film according to the invention is usually stored in a seam-sealed pouch without any other protective means. However, the OTF may also be on a detachable protective layer (release liner) from which it is removed immediately before application to the patient's oral cavity. Thus, the oral film may or may not further comprise a release liner. The oral film protected by a release liner is also usually stored in a seam-sealed pouch. The packaging may be child-resistant or child-friendly and / or elderly-friendly.

[0229] Preferred formulations for the matrix layer are listed in Tables A to H below:

[0230] Table A. Preferred substrate layer compositions

[0231]

[0232] Table B. Further preferred substrate layer compositions

[0233]

[0234]

[0235] Table C. Further preferred substrate layer compositions

[0236] Table D. Further preferred substrate layer compositions

[0237] Table E. Further preferred substrate layer compositions

[0238] Table F. Further preferred substrate layer compositions

[0239]

[0240] Table G. Further preferred substrate layer compositions

[0241] Table H. Further preferred substrate layer compositions

[0242]

[0243] The substrate layer having any one of the above formulations I to XXXIV preferably has a surface area of ​​50 to 300 g / m 2 , preferably 150 to 250 g / m 2 The area density of the oral film.

[0244] In a preferred embodiment, the matrix layer having any of the above formulations I to XXXIV is in the form of a smooth film, ie not a foamed film.

[0245] In a preferred embodiment, the substrate layer

[0246] comprising a total amount of 15 mg to 55 mg, preferably about 40 mg, of lurasidone hydrochloride,

[0247] having a formulation according to any one of formulations I to XXXIV above,

[0248] The area density of oral films is 50 to 300 g / m 2 , preferably 150 to 250 g / m 2 , and optionally

[0249] ·It is in the form of a smooth film.

[0250] Thus, in an exemplary embodiment, the matrix layer is characterized by:

[0251] comprising a total amount of 15 mg to 55 mg, preferably about 40 mg, of lurasidone hydrochloride,

[0252] ·Include

[0253] o 35 to 53 wt.% lurasidone,

[0254] o 5 to 30 wt.% of polyvinyl alcohol,

[0255] o 5 to 35 wt.% of polyvinyl alcohol-polyethylene glycol graft copolymer,

[0256] o 4 to 10 wt.% of a plasticizer selected from polyethylene glycol, glycerol and / or triacetin,

[0257] o 0.1 to 2 wt.% of an emulsifier selected from polyoxyethylene-(20)-sorbitan monooleate, polyoxyethylene-(20)-sorbitan monostearate and diacetyl esters of mono- and diglycerides,

[0258] o 5 to 15 wt.% of sweetener,

[0259] o 2.5 to 10 wt.% of flavoring agents,

[0260] o 0 to 2 wt.% of a colorant; and

[0261] The area density of oral films is 50 to 300 g / m 2 , preferably 150 to 250 g / m 2 .

[0262] Thus, in another exemplary embodiment, the matrix layer is characterized by:

[0263] comprising a total amount of 15 mg to 55 mg, preferably about 40 mg, of lurasidone hydrochloride,

[0264] ·Include

[0265] o 35 to 53 wt.% lurasidone,

[0266] o 5 to 30 wt.% of polyvinyl alcohol,

[0267] o 5 to 35 wt.% of polyvinyl alcohol-polyethylene glycol graft copolymer,

[0268] o 4 to 10 wt.% of a plasticizer selected from polyethylene glycol, glycerol and / or triacetin,

[0269] o 0.1 to 2 wt.% emulsifier, the emulsifier is selected from polyoxyethylene-

[0270] (20)-sorbitan monooleate, polyoxyethylene-(20)-sorbitan monostearate and diacetyl esters of mono- and diglycerides,

[0271] o 5 to 15 wt.% of sweetener,

[0272] o 2.5 to 10 wt.% of flavoring agents,

[0273] o 0 to 2 wt.% colorant;

[0274] The area density of oral films is 50 to 300 g / m 2 , preferably 80 to 150 g / m 2 or 150 to 250 g / m 2 ,and

[0275] ·It is in the form of a smooth film.

[0276] In yet another preferred embodiment, the oral film consists of a matrix layer having any one of the above-mentioned Formulations I to XXXIV.

[0277] In another preferred embodiment, the oral film consists of a matrix layer having any one of the above-mentioned formulations I to XXXIV, and the area density of the oral film is 50 to 300 g / m 2 , preferably 80 to 150 g / m 2 or 150 to 250 g / m 2 .

[0278] In yet another preferred embodiment, the oral film consists of a matrix layer having any one of the above-mentioned formulations I to XXXIV and being in the form of a smooth film, ie not a foamed film.

[0279] In yet another preferred embodiment, the oral film consists of a matrix layer

[0280] comprising a total amount of 15 mg to 55 mg, preferably about 40 mg, of lurasidone hydrochloride,

[0281] having a formulation according to any one of formulations I to XXXIV above,

[0282] The area density of oral films is 50 to 300 g / m 2 , preferably 80 to 150 g / m 2 or 150 to 250 g / m 2 , and optionally

[0283] ·It is in the form of a smooth film.

[0284] The oral film according to the invention preferably has a thickness of 0.5 cm 2 Up to 10cm 2 , especially preferably 2cm 2 Up to 8cm 2 or 4cm 2 Up to 5cm 2 , especially 2.5cm 2 or 5cm 2 area.

[0285] Preferably, the oral film according to the present invention is also characterized in that the matrix layer contains 40 to 45 wt.% of lurasidone hydrochloride, 18 to 22 wt.% of polyvinyl alcohol-polyethylene glycol graft copolymer, and 10 to 15 wt.% of polyvinyl alcohol with an average molecular weight of 20,000 to 40,000 g / mol, especially 31,000 g / mol, each based on the total weight of the matrix layer.

[0286] Preferably, the oral film according to the present invention is also characterized in that the matrix layer contains 42.5 wt.% of lurasidone hydrochloride, 20.5 wt.% of polyvinyl alcohol-polyethylene glycol graft copolymer, and 13.5 wt.% of polyvinyl alcohol with an average molecular weight of 20,000 to 40,000 g / mol, especially 31,000 g / mol, each based on the total weight of the matrix layer.

[0287] In a particularly preferred embodiment, the oral film has a formulation according to Formulation A, F or G as described in Table 1, in particular Formulation A.

[0288] In a very particularly preferred embodiment, the oral film comprises

[0289] - 42.535 wt.% wt.% of lurasidone hydrochloride, preferably micronized to a D of 3 to 20 μm, especially 4 to 5 μm 90 (determined by laser diffraction analysis),

[0290] - 20.57 wt.% of a polyvinyl alcohol-polyethylene glycol graft copolymer, in particular a polyethylene glycol backbone onto which polyvinyl alcohol units are grafted, wherein the molar ratio of polyethylene glycol to polyvinyl alcohol is 1:3 and / or wherein the polyvinyl alcohol-polyethylene glycol graft copolymer has an average molecular weight in the range of 40,000 to 50,000 g / mol, preferably about 45,000 g / mol (determined by gel permeation chromatography),

[0291] 13.57 wt. % of polyvinyl alcohol having an average molecular weight of 20 000 to 40 000 g / mol, in particular 31 000 g / mol (determined by gel permeation chromatography),

[0292] - 6.13 wt.% wt.% of triacetin,

[0293] - 2.33 wt.% sucralose,

[0294] - 8.26 wt.% sorbitol,

[0295] -0.1wt.%wt.% neotame,

[0296] - 5 wt.% wt.% of a first flavoring agent, in particular cherry flavoring,

[0297] - 0.5 wt.% wt.% of a second flavoring agent, in particular peppermint oil,

[0298] - 0.005 wt.% wt.% of a colorant, in particular erythrosine,

[0299] -1.00wt.%wt.%Polysorbate 80,

[0300] and optionally residual process solvent, in particular water.

[0301] The dry area weight of the oral film is preferably between 180 and 190 g / m 2 In the range, especially 188g / m 2 .

[0302] The loading of lurasidone hydrochloride per oral film is preferably 20 mg or 40 mg.

[0303] The size of the oral film is preferably 2.5 cm 2 or 5cm 2 .

[0304] In another very particularly preferred embodiment, the oral film comprises

[0305] - 42.535 wt.% wt.% of lurasidone hydrochloride, which is micronized to a D of 3 to 20 μm, especially 4 to 5 μm 90 (determined by laser diffraction analysis),

[0306] - 20.57 wt.% of a polyvinyl alcohol-polyethylene glycol graft copolymer, which is a polyethylene glycol backbone onto which polyvinyl alcohol units are grafted, wherein the molar ratio of polyethylene glycol to polyvinyl alcohol is 1:3 and wherein the average molecular weight of the polyvinyl alcohol-polyethylene glycol graft copolymer is about 45000 g / mol (as determined by gel permeation chromatography),

[0307] 13.57 wt.% wt.% of polyvinyl alcohol having an average molecular weight of about 31000 g / mol (as determined by gel permeation chromatography),

[0308] - 6.13 wt.% wt.% of triacetin,

[0309] - 2.33wt.% sucralose,

[0310] - 8.26 wt.% sorbitol,

[0311] -0.1wt.% neotame,

[0312] - 5 wt.% of a first flavoring agent, which is cherry flavoring,

[0313] - 0.5 wt.% of a second flavoring agent, which is peppermint oil,

[0314] - 0.005 wt.% of a colorant, which is erythrosine,

[0315] -1.00wt.% polysorbate 80,

[0316] and optionally residual process solvent, in particular water.

[0317] The dry area weight of the oral film is preferably 188 g / m 2 .

[0318] The loading of lurasidone hydrochloride per oral film is preferably 20 mg or 40 mg.

[0319] The size of the oral film is preferably 2.5 cm 2 or 5cm 2 .

[0320] Preparation method

[0321] The oral film according to the present invention can be prepared by conventional methods.

[0322] The above-mentioned definition regarding the oral film also applies to the method according to the invention.

[0323] The method for manufacturing the oral film according to the present invention comprises the following steps:

[0324] a) preparing a dispersion comprising lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol having an average molecular weight of 20,000 to 250,000 g / mol, in particular 20,000 to 40,000 g / mol;

[0325] b) spreading the dispersion from step a), and

[0326] c) drying the spread dispersion to obtain an oral film.

[0327] It is to be understood that lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer, and at least one polyvinyl alcohol are described above in the context of a matrix layer.

[0328] The method for preparing the oral film according to the present invention preferably comprises the following steps:

[0329] a) preparing a solution, dispersion or melt comprising lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol having an average molecular weight of 20,000 to 40,000 g / mol;

[0330] a1) foaming the solution, dispersion or melt from step a), optionally by introducing a gas or a gas mixture, by chemical gas generation or by expansion of a dissolved gas,

[0331] b) spreading the solution, dispersion or melt from step a) or the optionally foamed solution, dispersion or melt from step a1),

[0332] c) drying the spread solution, dispersion or melt from step b) to obtain an oral film.

[0333] It is clear to the person skilled in the art that step a1) is only necessary if the matrix layer is to be provided in the form of a cured foam having cavities.

[0334] The gas bubbles or cavities are preferably produced by means of a foaming machine, with which the diameter of the gas bubbles can be set almost arbitrarily within a wide range.

[0335] The process solvent in step a) and / or a1) preferably comprises water or is water.

[0336] The drying in step c) preferably comprises drying at about 30 to 60° C. for about 15 to 60 minutes, in particular 30 minutes.

[0337] In a preferred embodiment, before performing step a), the lurasidone or a pharmaceutically acceptable salt thereof of step a) is subjected to one or more of the following steps: grinding, deagglomeration and / or micronization. These methods are well known to the skilled person and can be performed by any means commonly used in the art, such as ball milling, jet milling, cryogenic milling, high pressure homogenization, high shear mixing, wet milling and / or ultrasonic milling.

[0338] The oral film comprising the matrix layer can be manufactured using the above method, using further manufacturing steps as known to those skilled in the art, such as punching out individual oral films and packaging, for example by sealing in pouches of primary packaging material. These further steps preferably result in a mucoadhesive layer structure or oral film, as described in the preceding sections.

[0339] The present invention also relates to an oral film obtainable by the above method.

[0340] The film obtainable by the above-described method may have any or all of the properties as described above in the context of the substrate layer.

[0341] Treatment methods / medical uses

[0342] Furthermore, the present invention relates to an oral film as described above or an oral film obtainable by the method as described above as a medicament.

[0343] Furthermore, the present invention relates to an oral film as described above or obtainable by the above method as a medicament for lingual, sublingual and / or buccal administration, in particular for lingual administration. In certain embodiments, the OTF of the present invention is administered sublingually and swallowed after rapid disintegration, i.e., in certain embodiments, the OTF is an orodispersible film.

[0344] Furthermore, the present invention relates to an oral film as described above or an oral film obtainable by the method as described above for use in the treatment of psychiatric disorders, in particular schizophrenia, depression and / or bipolar disorder.

[0345] The present invention also relates to the use of an oral film as described above for the preparation of a medicament as described herein.

[0346] The present invention also relates to a method for treating a patient, comprising applying the above-described oral film, in particular a rapidly disintegrating oral film, to the tongue in the patient's mouth.

[0347] The present invention also relates to a method for treating psychiatric disorders, in particular schizophrenia, depression and / or bipolar disorder, comprising applying an oral film as described above, in particular a rapidly disintegrating oral film, to the tongue in the patient's mouth.

[0348] According to the above, the present invention also relates to a method for treating a disease, comprising administering to a patient in need thereof an oral film as described above or obtainable by the method described above. The disease is preferably selected from psychiatric diseases, in particular schizophrenia, depression and / or bipolar disorder.

[0349] According to the above, the present invention also relates to an oral film as described above or obtainable by the above method for use in a method of treatment. In a related aspect, the present invention also relates to an oral film as described above or obtainable by the above method for use in the treatment of mental illness, in particular schizophrenia, depression and / or bipolar disorder.

[0350] The patient is preferably a human patient, more preferably a child, an adult or an elderly person. Example

[0351] A number of oral thin films were prepared by the method according to the present invention and further analyzed.

[0352] Unless otherwise stated, the following method is used to prepare the oral film of the examples. The formulations are prepared by appropriate standard laboratory equipment. First, lurasidone hydrochloride is weighed in a batch production container. Thereafter, the process solvent is added, followed by the remaining excipients. No specific order is required for the addition of the excipients. The material is stirred for at least 4 hours. Homogenize with an UltraTurax homogenizer. Degas the material for at least overnight. The material is coated on a siliconized paper intermediate release liner using a coating knife with an appropriate gap width. The sample is dried using a heating and drying oven.

[0353] "Kollicoat IR" is a polyvinyl alcohol-polyethylene glycol graft copolymer having an average molecular weight of about 45,000 g / mol and a PEG / PVA monomer unit ratio of about 25:75.

[0354] "PVA 4-88" is a partially hydrolyzed polyvinyl alcohol having a degree of hydrolysis of about 88% and an average molecular weight of 31,000 g / mol.

[0355] "PVA 5-88" is a partially hydrolyzed polyvinyl alcohol having a degree of hydrolysis of about 88% and an average molecular weight of 37,000 g / mol.

[0356] "PVA 40-88" is a partially hydrolyzed polyvinyl alcohol having a degree of hydrolysis of about 88% and an average molecular weight of 205,000 g / mol.

[0357] "PEG 400" is polyethylene glycol with an average molecular weight of 400 g / mol.

[0358] "Polysorbate 80" is polyoxyethylene (20) sorbitan monooleate.

[0359] FD&C Red No. 40 is Allura Red AC (disodium 7-hydroxy-5-[(2-methoxy-5-methyl-4-sulfonatophenyl)diazenyl]naphthalene-2-sulfonate).

[0360] The compositions of these oral films are summarized in Table 1.

[0361]

[0362]

[0363] Example 1: Formulations A to G

[0364] Formulation A showed the best results as it provided a smooth, non-brittle oral film into which a large amount of API could be incorporated.

[0365] The oral film according to formulation A further showed close to commercially available Dissolution profile of 40 mg tablets.

[0366] Preferred are oral films of formulation A wherein the API is present in micronized form with the following parameters (as determined by laser diffraction):

[0367] D 0.1 0μm

[0368] D 50 2μm

[0369] D 90 4.759μm

[0370] The oral film of Formulation A, in which the API was present in micronized form with the following parameters, was less preferred as it showed a rougher surface and higher brittleness (as determined by laser diffraction):

[0371] D 0.1 8μm

[0372] D 50 56μm

[0373] D 90 213μm

[0374] The oral films of formulations B, C, D and E showed too long a disintegration time due to the use of high molecular weight polyvinyl alcohol 40-88 having an average molecular weight of about 205000 g / mol.

[0375] The disintegration time of Formulation A was measured according to European Pharmacopoeia (Ph. Eur.) 2.9.1 as described below. The disintegration time of Formulations B, C, D and E was estimated by placing the corresponding OTF in a flat bowl filled with water and visually observing.

[0376] The oral film of Formulation F showed good disintegration time, good flexibility and no brittleness. In addition, the oral film of Formulation E could be improved by increasing the amount of plasticizer.

[0377] The oral films of Formulations F and G showed very similar characteristics to the oral film of Formulation A.

[0378] The incorporation of flavoring agents may change the surface tension of the composition, which may lead to wetting problems, resulting in defective oral films. To overcome this possible disadvantage, emulsifiers such as polysorbate 80 may be added.

[0379] Example 2: Further Characterization of Formulation A

[0380] According to the method of the present invention, water was used as the process solvent to prepare an oral film according to formulation A. Drying was carried out in a laboratory drying oven using the following parameters.

[0381] 1.30℃, duration: 10 minutes

[0382] 2. Heating program from 30℃ to 60℃, duration: 10 minutes

[0383] 3.60℃, duration: 10 minutes

[0384] The resulting oral film showed a residual moisture of 3.5%. The determination was performed by Karl Fischer titration using a Metrohm 874 oven sample processor and a 851 KF Titrando.

[0385] In addition, the disintegration time of Formulation A was measured.

[0386] Apparatus: Disintegration measuring device according to Ph.Eur. 2.9.1

[0387] Buffer: Phosphate citrate buffer, pH 7.1

[0388] Temperature: 37±2℃

[0389] Frequency: 29-32 cycles

[0390] For measurement, the area is 5cm 2The oral film of formulation A of 100% was tested. For the test, the oral film was rolled up and placed in a spiral sinker basket (e.g., Sotax) to avoid floating of the oral film. The sinker basket was then placed in the basket holder of the disintegration tester (1 sinker basket per tube). The measurement was then started and the decay was visually checked.

[0391] Six measurements were performed and the results are summarized in Table 2:

[0392] Table 2: Disintegration time measurement results of oral films of Formulation A.

[0393] Measurement Disintegration time [s] 1 46 2 45 3 45 4 37 5 40 6 40 average 42 RSD disintegration time 8.7%

[0394] For commercial The dissolution of the 40 mg tablets was measured and is summarized in Table 3:

[0395] Table 3: Dissolution times of 40 mg tablets at different pH values ​​are given as the percentage of lurasidone released from the tablet drug load.

[0396]

[0397]

[0398] As shown in the data in Table 3, lurasidone hydrochloride tablets ( 40 mg) dissolved rapidly in pH 1.2 (JP), pH 3.8 (JP) and pH 4.0 (JP) dissolution media, and dissolved slowly in water.

[0399] Table 4: Dissolution time of oral film compositions at different pH values ​​(average value)

[0400]

[0401] The following test conditions were used In vitro dissolution test of tablets and formulation A: In vitro release analysis was performed according to the parameters for in vitro release test of lurasidone tablets mentioned in the FDA webpage (https: / / www.accessdata.fda.gov / scripts / cder / dissolution / index.cfm(22.04.2022)). According to the FDA information, USP apparatus II (paddle) was used. However, an additional sinker was included to fix the OTF to the bottom of the container at the beginning of the analysis. The stirring speed was 50 rpm. The analysis was performed at 37°C ± 0.5°C using 900 mL of one of the four release media.

[0402] The following four release media were used:

[0403] Release medium pH 1.2: dilute hydrochloric acid solution.

[0404] Release medium pH 3.8: mixture of disodium hydrogen phosphate buffer and citrate buffer.

[0405] Release medium pH 4.5: mixture of disodium hydrogen phosphate buffer and citrate buffer.

[0406] Release medium pH 6.8: mixture of disodium hydrogen phosphate buffer and citrate buffer.

[0407] Figure 1 and Figure 2 It is further shown that the active agent changes from Release from 40 mg tablets and oral thin films of Formulation A.

[0408] Figure 1 The data shown in The oral thin film according to Formulation A had a faster dissolution time in low pH buffer compared to the 40 mg tablet.

[0409] Therefore, OTF was considered bioequivalent to Latuda tablets.

[0410] Figure 2 The data presented in show that the oral film according to Formulation A showed a slower dissolution time at higher pH values.

[0411] Example 3: Oral Film of Prior Art

[0412] Comparison of the OTF of Formulation A with film compositions known from the prior art.

[0413] Table 5 summarizes the known film compositions from Prabhu et al., Int J App Pharm, Vol. 13, No. 1, 2021, 170-177. The disintegration time was determined as described therein: visually in a petri dish containing 10 mL of phosphate buffer, pH 6.8, i.e. the disintegration time was noted once the film ruptured and slowly disintegrated.

[0414]

[0415] The film compositions known from Prabhu et al., Int J App Pharm, Vol. 13, No. 1, 2021, 170-177 show a longer disintegration time compared to the oral film of formulation A and have the disadvantage that these films are brittle due to the use of HPMC and have other disadvantages because they exhibit an unpleasant (sticky) feeling in the user's mouth. In addition, the compositions according to Prabhu et al. do not disintegrate in the same manner as the oral film of formulation A. The tablets were bioequivalent because the composition of Prabhu et al. resulted in a faster C 2 0.5 mmol / l compared to the tablets. max .

[0416] The film compositions from CN112618518A are summarized in Table 6. Disintegration time was determined as described therein: Filter paper was moistened with purified water and laid flat on a petri dish. The finished film was placed on top of the moistened filter paper. The time required for complete disintegration of the film was recorded.

[0417]

[0418] The film compositions known from CN 112618518 A show fast disintegration times. However, these films are nevertheless disadvantageous in that they are brittle due to the use of HPMC and they have further disadvantages in that they exhibit an unpleasant (sticky) feel in the user's mouth.

[0419] Example 4: Formulations J to O

[0420] Additional OTFs were prepared according to formulations J to O and compared with formulation A. Their compositions and results are summarized in Table 7.

[0421] By folding in the bag the size is 5cm 2 The folding test is performed on a single unit of (2 x 2:5 cm). The folded sample represents the worst case in terms of the possible physical stress that can be transferred to the sample. For the analysis, the packaging material is folded by about 170°-180° at the location of the single unit of the bagged test article. A standard 2 kg tube is then rolled twice on the folded edge. Afterwards, the packaging material is cut open. By carefully removing the sample from the packaging material, it is determined whether the sample is still intact or broken into two parts.

[0422] The tensile strength is measured according to the following method: A single unit of the test product is fixed with two jaws in a tensile strength tester. The distance between the upper and lower jaws should be 10 mm. While the sample is fixed, the upper clamp moves upwards at a speed of 300 mm / min over a measuring path of 10 mm. The maximum force required to tear a single unit is determined in Newtons (N).

[0423] Disintegration was determined according to the European Pharmacopoeia as described above.

[0424] The puncture strength is determined as follows: A digital dynamometer is fixedly mounted. The sample (20 x 25 mm) is fixed to the edge and pressed against the test surface of the device (circular test surface with a diameter of 5 mm). The applied force is increased until the OTF is punctured. The maximum value of the force (N) acting on the specimen until it is punctured or ruptured is recorded. The measurement is performed with n = 3 laminated samples per batch.

[0425] Formulations N and O exhibit such high brittleness that they break during removal of the intermediate release liner (see table below, indicating that these formulations are not processable), indicating that it is challenging to formulate OTFs with very high loadings of lurasidone hydrochloride, and that it may be preferable to limit the concentration of lurasidone hydrochloride to less than 60 wt.%, such as less than 55 wt.% or 53 wt.%. Formulations A and J to M exhibit acceptable mechanical properties and disintegration behavior. In particular, formulation A has excellent tensile strength, indicating that this formulation produces an OTF with particularly beneficial mechanical properties. For example, formulation J still exhibits acceptable tensile strength. Formulation K exhibits the highest puncture strength, which further supports that, on average, low molecular weight PVA can be used beneficially if particularly high mechanical strength is required. On the other hand, the disintegration time is less affected by the molecular weight of the PVA, indicating that the mechanical properties can be fine-tuned while maintaining a good disintegration curve.

[0426]

[0427] Example 5: Stability Study

[0428] Two different sizes of OTF (2.5 cm 2 and 5cm 2 ). The tests were conducted at 40°C / 75%RH for 6 months, at 25°C / 60%RH for 9 months, and at 30°C / 65%RH for 10 months. All measurements were repeated six times. It was found that all OTFs stored under all conditions met the required test parameters. For example, for a 5 cm 2 OTF determines the following test parameters (average values):

[0429] Appearance: Meets the requirements, light pink opaque OTF, no abnormalities

[0430] Content: 102.7%

[0431] Dissolution after 45 minutes according to European Pharmacopoeia 2.9.3: 98%

[0432] Content uniformity according to European Pharmacopoeia 2.9.40: meets the requirements

[0433] Degradation products: Total impurities < 0.1%

[0434] Disintegration time: 48s

[0435] Water content: 5.2%

[0436] Folding test: Meets the requirements

[0437] Tensile strength: 8.6N

[0438] The present invention particularly relates to the following further embodiments:

[0439] 1. An oral film comprising a matrix layer, wherein the matrix layer comprises lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol having an average molecular weight of 20,000 to 40,000 g / mol.

[0440] 2. The oral film according to embodiment 1, wherein lurasidone or a pharmaceutically acceptable salt thereof is provided in the matrix layer in an amount of 35 to 50 wt.%, preferably 40 to 45 wt.%, relative to the total weight of the matrix layer.

[0441] 3. The oral film according to any one of the preceding embodiments, wherein at least one polyvinyl alcohol-polyethylene glycol graft copolymer has a polyethylene glycol backbone onto which polyvinyl alcohol units are grafted.

[0442] 4. The oral film according to any one of the preceding embodiments, wherein at least one polyvinyl alcohol-polyethylene glycol graft copolymer has a polyethylene glycol backbone with grafted polyvinyl alcohol units thereon, wherein the molar ratio of polyethylene glycol to polyvinyl alcohol is 1:3.

[0443] 5. The oral film according to any one of the preceding embodiments, wherein the average molecular weight of at least one polyvinyl alcohol-polyethylene glycol graft copolymer ranges from 40,000 to 50,000 g / mol, preferably about 45,000 g / mol.

[0444] 6. The oral film according to any one of the preceding embodiments, wherein at least one polyvinyl alcohol is provided in the matrix layer in an amount of 5 to 20 wt.%, preferably 10 to 15 wt.%, relative to the total weight of the matrix layer.

[0445] 7. The oral film according to any one of the preceding embodiments, wherein at least one polyvinyl alcohol-polyethylene glycol graft copolymer is provided in the matrix layer in an amount of 10 to 35 wt.%, preferably 15 to 25 wt.%, relative to the total weight of the matrix layer.

[0446] 8. The oral film according to any one of the preceding embodiments, wherein the matrix layer comprises at least one plasticizer.

[0447] 9. The oral film according to any one of the preceding embodiments, wherein the matrix layer comprises at least one emulsifier.

[0448] 10. The oral film according to any one of the preceding embodiments, wherein the matrix layer further comprises at least one auxiliary substance selected from colorants, flavoring agents, sweeteners, taste masking agents, enhancers, pH adjusters, wetting agents, preservatives and / or antioxidants.

[0449] 11. The oral film according to any one of the preceding embodiments, wherein lurasidone or a pharmaceutically acceptable salt thereof is present in the form of microparticles, particularly in the form of D 90 The nanoparticles are present in the form of particles with a size of 1 to 20 μm, preferably 1 to 10 μm.

[0450] 12. The oral film according to any one of the preceding embodiments, wherein lurasidone or a pharmaceutically acceptable salt thereof is substantially insoluble in the matrix layer.

[0451] 13. The oral film according to any one of the preceding embodiments, wherein the oral film has an area density of 50 to 300 g / m 2 , preferably 150 to 250 g / m 2 .

[0452] 14. The oral film according to any one of the preceding embodiments, wherein lurasidone or a pharmaceutically acceptable salt thereof comprises a total amount of 25 to 55 mg, preferably about 40 mg, of lurasidone hydrochloride.

[0453] 15. The oral film according to any one of the preceding embodiments, wherein at least 70% or at least 80% of lurasidone or a pharmaceutically acceptable salt thereof is released within the first 15 minutes after administration at a pH of 3.8.

[0454] 16. The oral film according to any one of the preceding embodiments, wherein the oral film comprises:

[0455] - 42.535wt.% of lurasidone hydrochloride,

[0456] - 20.57 wt.% of polyvinyl alcohol-polyethylene glycol graft copolymer,

[0457] 13.57 wt. % of polyvinyl alcohol having an average molecular weight of 20,000 to 40,000 g / mol, in particular 31,000 g / mol,

[0458] - 6.13 wt.% of triacetin,

[0459] -2.33wt.% sucralose,

[0460] -8.26wt.% sorbitol,

[0461] -0.1wt.%neotame,

[0462] - 5 wt.% of a first flavoring agent, in particular cherry flavoring,

[0463] - 0.5 wt.% of a second flavoring agent, in particular peppermint oil,

[0464] - 0.005 wt.% of coloring agent, especially erythrosine,

[0465] -1.00wt.% Polysorbate 80,

[0466] and optionally residual process solvent, in particular water.

[0467] 17. A method for preparing an oral film according to any one of the preceding embodiments, comprising the steps of:

[0468] a) preparing a solution, dispersion or melt comprising lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol having an average molecular weight of 20,000 to 40,000 g / mol;

[0469] a1) foaming the solution, dispersion or melt from step a), optionally by introducing a gas or a gas mixture, by chemical gas generation or by expansion of a dissolved gas,

[0470] b) spreading the solution, dispersion or melt from step a), or the optionally foamed solution, dispersion or melt from step a1),

[0471] c) drying the spread solution, dispersion or melt from step b) to obtain an oral film.

[0472] 18. An oral thin film according to any one of embodiments 1 to 16 or obtainable by a process according to embodiment 17 for use as a medicament.

[0473] 19. An oral thin film according to any one of embodiments 1 to 16 or obtainable by a process according to embodiment 17, for use in the treatment of psychiatric disorders, in particular schizophrenia, depression and / or bipolar disorder.

[0474] The present invention particularly relates to the following other items:

[0475] 1. An oral film comprising a matrix layer, wherein the matrix layer comprises lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol having an average molecular weight of 20,000 to 40,000 g / mol.

[0476] 2. The oral film according to item 1, wherein the lurasidone or a pharmaceutically acceptable salt thereof is provided in the matrix layer in an amount of 35 to 55 wt.%, preferably 35 to 53 wt.%, more preferably 40 to 45 wt.%, relative to the total weight of the matrix layer.

[0477] 3. The oral film according to item 1 or 2, wherein the at least one polyvinyl alcohol-polyethylene glycol graft copolymer has a polyethylene glycol backbone chain onto which polyvinyl alcohol units are grafted.

[0478] 4. The oral film according to any one of the preceding items, wherein the molar ratio of the polyethylene glycol monomer unit to the polyvinyl alcohol monomer unit is 1:3.

[0479] 5. The oral film according to any of the preceding items, wherein the average molecular weight of the at least one polyvinyl alcohol-polyethylene glycol graft copolymer is in the range of 40,000 to 50,000 g / mol, preferably about 45,000 g / mol.

[0480] 6. The oral film according to any of the preceding items, wherein the at least one polyvinyl alcohol is provided in the matrix layer in an amount of 5 to 30 wt.%, preferably 10 to 25 wt.%, relative to the total weight of the matrix layer.

[0481] 7. The oral film according to any of the preceding items, wherein the at least one polyvinyl alcohol-polyethylene glycol graft copolymer is provided in the matrix layer in an amount of 5 wt.% to 35 wt.%, preferably 10 wt.% to 30 wt.%, relative to the total weight of the matrix layer.

[0482] 8. The oral film according to any one of the preceding items, wherein the at least one polyvinyl alcohol-polyethylene glycol graft copolymer and the at least one polyvinyl alcohol are present in a combined amount of 25 to 65 wt.%, preferably 30 to 60 wt.%, more preferably 30 to 45 wt.%, relative to the total weight of the matrix layer.

[0483] 9. The oral film according to any of the preceding items, wherein the matrix layer comprises at least one plasticizer, preferably selected from polyethylene glycol, glycerol and triacetin, preferably wherein the at least one plasticizer is triacetin.

[0484] 10. The oral film according to item 8, wherein the plasticizer is present in an amount of 1 to 15 wt.%, preferably 4 to 10 wt.%, most preferably 5 to 10 wt.%.

[0485] 11. The oral film according to any one of the preceding items, wherein the matrix layer comprises at least one emulsifier, preferably selected from polyoxyethylene-(20)-sorbitan monooleate, polyoxyethylene-(20)-sorbitan monostearate, diacetyl esters of monoglycerides and diglycerides, most preferably wherein the emulsifier is polyoxyethylene-(20)-sorbitan monooleate.

[0486] 12. The oral film according to any one of the preceding items, wherein the matrix layer comprises at least one emulsifier in an amount of 0.1 wt.% to 2 wt.%, preferably 0.5 wt.% to 1.5 wt.%, relative to the total weight of the matrix layer.

[0487] 13. The oral film according to any one of the preceding items, wherein the matrix layer further comprises at least one auxiliary substance selected from the group consisting of colorants, flavoring agents, sweeteners, taste masking agents, enhancers, pH regulators, wetting agents, preservatives and / or antioxidants.

[0488] 14. The oral film according to any one of the preceding items, wherein the lurasidone or a pharmaceutically acceptable salt thereof is present in the form of microparticles, preferably having

[0489] -D 90 1 to 100 μm, preferably 1 to 10 μm, and / or

[0490] -D 50 It is 0.1 to 25 μm, preferably 0.5 to 5 μm.

[0491] 15. The oral thin film according to any one of the preceding items, wherein the lurasidone or a pharmaceutically acceptable salt thereof is substantially insoluble in the matrix layer.

[0492] 16. The oral film according to any of the preceding claims, wherein the area density of the oral film is 50 to 300 g / m 2 , preferably 150 to 250 g / m 2 .

[0493] 17. The oral film according to any one of the preceding items, wherein the lurasidone or a pharmaceutically acceptable salt thereof is provided in the matrix layer in an amount of 35 to 55 wt.%, preferably 35 to 53 wt.%, relative to the total weight of the matrix layer, and wherein the area density of the oral film is 50 to 300 g / m 2 , preferably 150 to 250 g / m 2 .

[0494] 18. The oral film according to any one of the preceding items, wherein the lurasidone or a pharmaceutically acceptable salt thereof comprises a total amount of 15 mg to 55 mg, preferably 25 mg to 55 mg, most preferably about 40 mg of lurasidone hydrochloride.

[0495] 19. The oral film according to any one of the preceding items, which has an in vitro disintegration time of 10 to 120 seconds, preferably 15 to 60 seconds.

[0496] 20. The oral film according to any one of the preceding items, which has a tensile strength of 3 to 15N, preferably 5 to 15N.

[0497] 21. The oral film according to any of the preceding items, wherein at least 80% of lurasidone or a pharmaceutically acceptable salt thereof is released within the first 15 minutes after immersion in an aqueous solution at a temperature of 37±0.5°C and a pH of 1.2, and / or at least 90% of lurasidone or a pharmaceutically acceptable salt thereof is released within the first 15 minutes after immersion in an aqueous solution at a temperature of 37±0.5°C and a pH of 3.8.

[0498] 22. The oral film according to any of the preceding items, wherein at least 70% or at least 80% of lurasidone or a pharmaceutically acceptable salt thereof is released within the first 15 minutes after immersion in an aqueous solution having a pH of 3.8.

[0499] 23. The oral film according to any one of the preceding items, wherein the oral film comprises:

[0500] - 40 to 45 wt.% of lurasidone hydrochloride,

[0501] - 10 to 25 wt.% of polyvinyl alcohol-polyethylene glycol graft copolymer,

[0502] - 10 to 25 wt.% of polyvinyl alcohol having an average molecular weight of 20,000 to 40,000 g / mol,

[0503] - 4 to 10 wt.% of a plasticizer, in particular glycerol triacetate,

[0504] - 5 to 15 wt.% of a sweetener, preferably a mixture of sucralose, sorbitol and neotame,

[0505] - 2.5 to 7.5 wt. % of a first flavoring, in particular cherry flavoring,

[0506] - 0 to 2.5 wt.% of a second flavoring agent, in particular peppermint oil,

[0507] - 0 to 2 wt.% of colorants, especially erythrosine,

[0508] - 0.5 to 2 wt.% of emulsifier, in particular polyoxyethylene-(20)-sorbitan monooleate, and optionally residual process solvent, in particular water.

[0509] 24. The oral thin film according to any one of the preceding items, wherein the oral thin film is obtainable by drying a coated coating composition comprising lurasidone, polyvinyl alcohol, a polyvinyl alcohol-polyethylene glycol graft copolymer and water.

[0510] 25. A method for preparing an oral film, comprising:

[0511] a) preparing a dispersion comprising lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol having an average molecular weight of 20,000 to 40,000 g / mol;

[0512] b) spreading the dispersion from step a), and

[0513] c) drying the spread dispersion to obtain a matrix layer.

[0514] 26. The method according to item 25, wherein the oral film comprises or consists of the matrix layer.

[0515] 27. The method according to any one of items 25 or 26, wherein the lurasidone or a pharmaceutically acceptable salt thereof is provided in the matrix layer in an amount of 35 to 55 wt.%, preferably 35 to 53 wt.%, more preferably 40 to 45 wt.%, relative to the total weight of the matrix layer.

[0516] 28. The process according to any one of items 25 to 27, wherein the at least one polyvinyl alcohol has an average molecular weight of 20,000 to 40,000 g / mol.

[0517] 29. The method according to any one of items 25 to 28, wherein the at least one polyvinyl alcohol-polyethylene glycol graft copolymer has a polyethylene glycol backbone with grafted polyvinyl alcohol units thereon, preferably wherein the molar ratio of polyethylene glycol monomer units to polyvinyl alcohol monomer units is 1:3.

[0518] 30. The process according to any one of items 25 to 29, wherein the at least one polyvinyl alcohol-polyethylene glycol graft copolymer has an average molecular weight in the range of 40,000 to 50,000 g / mol, preferably about 45,000 g / mol.

[0519] 31. The method according to any one of items 25 to 30, wherein the at least one polyvinyl alcohol is provided in the matrix layer in an amount of 5 to 30 wt.%, preferably 10 to 25 wt.%, relative to the total weight of the matrix layer.

[0520] 32. The method according to any one of items 25 to 31, wherein the at least one polyvinyl alcohol-polyethylene glycol graft copolymer is provided in the matrix layer in an amount of 5 to 35 wt.%, preferably 10 to 30 wt.%, relative to the total weight of the matrix layer.

[0521] 33. The method according to any one of items 25 to 32, wherein the at least one polyvinyl alcohol-polyethylene glycol graft copolymer and the at least one polyvinyl alcohol are present in a combined amount of 25 to 65 wt.%, preferably 30 to 60 wt.%, more preferably 30 to 45 wt.%, based on the total weight of the substrate layer.

[0522] 34. The method according to any one of items 25 to 33, wherein the dispersion comprises at least one plasticizer, preferably selected from polyethylene glycol, glycerol and triacetin, preferably wherein the at least one plasticizer is triacetin.

[0523] 35. The method according to item 34, wherein the plasticizer is present in an amount of 1 to 15 wt.%, preferably 4 to 10 wt.%, most preferably 5 to 10 wt.%.

[0524] 36. A method according to any one of items 25 to 35, wherein the dispersion comprises at least one emulsifier, preferably selected from polyoxyethylene-(20)-sorbitan monooleate, polyoxyethylene-(20)-sorbitan monostearate, diacetyl esters of monoglycerides and diglycerides, most preferably wherein the emulsifier is polyoxyethylene-(20)-sorbitan monooleate.

[0525] 37. The method according to item 36, wherein the matrix layer comprises at least one emulsifier, the amount of the emulsifier is 0.1 to 2 wt.%, preferably 0.5 to 1.5 wt.%, relative to the total weight of the matrix layer.

[0526] 38. The method according to any one of items 25 to 37, wherein the matrix layer further comprises at least one auxiliary substance selected from the group consisting of colorants, flavoring agents, sweeteners, taste masking agents, enhancers, pH regulators, wetting agents, preservatives and / or antioxidants.

[0527] 39. The method according to any one of items 25 to 38, wherein lurasidone or a pharmaceutically acceptable salt thereof is present in the form of microparticles, preferably having

[0528] -D 90 1 to 100 μm, preferably 1 to 10 μm, and / or

[0529] -D 50 It is 0.1 to 25 μm, preferably 0.5 to 5 μm.

[0530] 40. The method according to any one of items 25 to 39, wherein the lurasidone or a pharmaceutically acceptable salt thereof is substantially insoluble in the dispersion and the matrix layer.

[0531] 41. The method according to any one of items 25 to 40, wherein the area density of the oral film is 50 to 300 g / m 2 , preferably 150 to 250 g / m 2 .

[0532] 42. The method according to any one of items 25 to 41, wherein the lurasidone or a pharmaceutically acceptable salt thereof is provided in the matrix layer in an amount of 35 to 55 wt.%, preferably 35 to 53 wt.%, relative to the total weight of the matrix layer, and wherein the area density of the oral film is 50 to 300 g / m 2 , preferably 150 to 250 g / m 2 .

[0533] 43. The method according to any one of items 25 to 42, wherein the lurasidone or a pharmaceutically acceptable salt thereof comprises a total amount of 15 mg to 55 mg, preferably 25 mg to 55 mg, most preferably about 40 mg of lurasidone hydrochloride.

[0534] 44. The method according to any one of items 25 to 43, wherein the oral film has an in vitro disintegration time of 10 to 120 seconds, preferably 15 to 60 seconds.

[0535] 45. The method according to any one of items 25 to 44, wherein the tensile strength of the oral film is in the range of 3-15N, preferably 5-15N.

[0536] 46. ​​A method according to any one of items 25 to 45, wherein the oral film releases at least 80% of lurasidone or a pharmaceutically acceptable salt thereof within the first 15 minutes after being immersed in an aqueous solution with a pH value of 1.2 at a temperature of 37±0.5°C, and / or releases at least 90% of lurasidone or a pharmaceutically acceptable salt thereof within the first 15 minutes after being immersed in an aqueous solution with a pH value of 3.8 at a temperature of 37±0.5°C.

[0537] 47. The method according to any one of items 25 to 46, wherein at least 70% or at least 80% of lurasidone or a pharmaceutically acceptable salt thereof is released within the first 15 minutes after immersion in an aqueous solution having a pH of 3.8.

[0538] 48. The method according to any one of items 25 to 47, wherein the oral film comprises:

[0539] - 40 to 45 wt.% of lurasidone hydrochloride,

[0540] - 10 to 25 wt.% of polyvinyl alcohol-polyethylene glycol graft copolymer,

[0541] - 10 to 25 wt.% of polyvinyl alcohol having an average molecular weight of 20,000 to 40,000 g / mol,

[0542] - 4 to 10 wt.% of a plasticizer, in particular glycerol triacetate,

[0543] - 5 to 15 wt.% of a sweetener, preferably a mixture of sucralose, sorbitol and neotame,

[0544] - 2.5 to 7.5 wt. % of a first flavoring, in particular cherry flavoring,

[0545] - 0 to 2.5 wt.% of a second flavoring agent, in particular peppermint oil,

[0546] - 0 to 2 wt.% of colorants, especially erythrosine,

[0547] - 0.5 to 2 wt.% of emulsifier, in particular polyoxyethylene-(20)-sorbitan monooleate, and optionally residual process solvent, in particular water.

[0548] 49. The method according to any one of items 25 to 48, wherein the oral film is obtainable by drying a spread dispersion comprising lurasidone, polyvinyl alcohol, a polyvinyl alcohol-polyethylene glycol graft copolymer and water.

[0549] 50. An oral film according to any one of items 1 to 24 or obtainable by a process according to any one of items 25 to 49 for use as a medicament, preferably for the treatment of psychiatric disorders, in particular schizophrenia, depression and / or bipolar disorder.

[0550] 51. Use of an oral film according to any one of items 1 to 24 or an oral film obtainable by a process according to any one of items 25 to 49 for the preparation of a medicament, preferably for the treatment of mental illnesses, in particular schizophrenia, depression and / or bipolar disorder.

[0551] 52. A method of treatment comprising administering to a patient in need thereof an oral thin film according to any one of items 1 to 24 or an oral thin film obtainable by a method according to any one of items 25 to 49.

[0552] 53. The method of treatment of claim 52, wherein the method of treatment is a method of treating a mental illness, in particular schizophrenia, depression and / or bipolar disorder.

[0553] 54. The oral film for use according to item 50, the use of the oral film according to item 51 in the preparation of a medicament, or the treatment method according to any one of items 52 or 53, wherein the lurasidone or a pharmaceutically acceptable salt thereof is provided in the matrix layer in an amount of 35 to 55 wt.%, preferably 35 to 53 wt.%, more preferably 40 to 45 wt.%, relative to the total weight of the matrix layer.

[0554] 55. The oral film for use according to item 50 or 54, the use of the oral film according to item 51 or 54 in the preparation of a medicament, or the method of treatment according to any one of items 52, 53 or 54, wherein the at least one polyvinyl alcohol has an average molecular weight of 20,000 to 40,000 g / mol.

[0555] 56. An oral film for use according to any one of items 50, 54 and 55, use of an oral film according to any one of items 51, 54 and 55 in the preparation of a medicament, or a method of treatment according to any one of items 52 to 55, wherein the at least one polyvinyl alcohol-polyethylene glycol graft copolymer has a polyethylene glycol backbone with grafted polyvinyl alcohol units thereon, preferably wherein the molar ratio of polyethylene glycol monomer units to polyvinyl alcohol monomer units is 1:3.

[0556] 57. An oral film for use according to any one of items 50 and 54 to 56, use of an oral film according to any one of items 51 and 54 to 56 for the preparation of a medicament, or a method of treatment according to any one of items 52 to 56, wherein the at least one polyvinyl alcohol-polyethylene glycol graft copolymer has an average molecular weight in the range of 40,000 to 50,000 g / mol, preferably about 45,000 g / mol.

[0557] 58. An oral film for use according to any one of items 50 and 54 to 57, use of the oral film according to any one of items 51 and 54 to 57 in the preparation of a medicament, or a method of treatment according to any one of items 52 to 57, wherein the at least one polyvinyl alcohol is provided in the matrix layer in an amount of 5 to 30 wt.%, preferably 10 to 25 wt.%, relative to the total weight of the matrix layer.

[0558] 59. An oral film for use according to any one of items 50 and 54 to 58, use of the oral film according to any one of items 51 and 54 to 58 in the preparation of a medicament, or a method of treatment according to any one of items 52 to 58, wherein the at least one polyvinyl alcohol-polyethylene glycol graft copolymer is provided in the matrix layer in an amount of 5 to 35 wt.%, preferably 10 to 30 wt.%, relative to the total weight of the matrix layer.

[0559] 60. The oral film for use according to any one of items 50 and 54 to 59, the use of the oral film according to any one of items 51 and 54 to 59 in the preparation of a medicament, or the method of treatment according to any one of items 52 to 59, wherein the at least one polyvinyl alcohol-polyethylene glycol graft copolymer and the at least one polyvinyl alcohol are present in a combined amount of 25 to 65 wt.%, preferably 30 to 60 wt.%, more preferably 30 to 45 wt.%, based on the total weight of the matrix layer.

[0560] 61. An oral film for use according to any one of items 50 and 54 to 60, use of an oral film according to any one of items 51 and 54 to 60 for the preparation of a medicament, or a method of treatment according to any one of items 52 to 60, wherein the matrix layer comprises at least one plasticizer, preferably selected from polyethylene glycol, glycerol and triacetin, preferably wherein the at least one plasticizer is triacetin.

[0561] 62. The oral film for use according to item 61, the use of the oral film according to item 61 in the preparation of a medicament or the method of treatment according to item 61, wherein the plasticizer is present in an amount of 1 to 15 wt.%, preferably 4 to 10 wt.%, and most preferably 5 to 10 wt.%.

[0562] 63. An oral film for use according to any one of items 50 and 54 to 62, use of an oral film according to any one of items 51 and 54 to 62 for the preparation of a medicament, or a method of treatment according to any one of items 52 to 62, wherein the matrix layer comprises at least one emulsifier, the emulsifier is preferably selected from polyoxyethylene-(20)-sorbitan monooleate, polyoxyethylene-(20)-sorbitan monostearate, diacetyl esters of monoglycerides and diglycerides, most preferably wherein the emulsifier is polyoxyethylene-(20)-sorbitan monooleate.

[0563] 64. The oral film for use according to any one of items 50 and 54 to 63, the use of the oral film according to any one of items 51 and 54 to 63 in the preparation of a medicament, or the method of treatment according to any one of items 52 to 63, wherein the matrix layer comprises at least one emulsifier in an amount of 0.1 to 2 wt.%, preferably 0.5 to 1.5 wt.%, based on the total weight of the matrix layer.

[0564] 65. An oral film for use according to any one of items 50 and 54 to 64, use of the oral film according to any one of items 51 and 54 to 64 in the preparation of a medicament, or a method of treatment according to any one of items 52 to 64, wherein the matrix layer further comprises at least one auxiliary substance selected from the group consisting of colorants, flavoring agents, sweeteners, masking agents, enhancers, pH adjusters, wetting agents, preservatives and / or antioxidants.

[0565] 66. The oral film for use according to any one of items 50 and 54 to 65, the use of the oral film according to any one of items 51 and 54 to 65 in the preparation of a medicament, or the method of treatment according to any one of items 52 to 65, wherein the lurasidone or a pharmaceutically acceptable salt thereof is in the form of microparticles, preferably having

[0566] -D 90 1 to 100 μm, preferably 1 to 10 μm, and / or

[0567] -D 50 It is 0.1 to 25 μm, preferably 0.5 to 5 μm.

[0568] 67. The oral film for use according to any one of items 50 and 54 to 66, the use of the oral film according to any one of items 51 and 54 to 66 for the preparation of a medicament, or the method of treatment according to any one of items 52 to 66, wherein lurasidone or a pharmaceutically acceptable salt thereof is substantially insoluble in the matrix layer.

[0569] 68. The oral film for use according to any one of items 50 and 54 to 67, the use of the oral film according to any one of items 51 and 54 to 67 in the preparation of a medicament, or the method of treatment according to any one of items 52 to 67, wherein the area density of the oral film is 50 to 300 g / m 2 , preferably 150 to 250 g / m 2 .

[0570] 69. The oral film for use according to any one of items 50 and 54 to 68, the use of the oral film according to any one of items 51 and 54 to 68 in the preparation of a medicament, or the method of treatment according to any one of items 52 to 68, wherein the lurasidone or a pharmaceutically acceptable salt thereof is provided in the matrix layer in an amount of 35 to 55 wt.%, preferably 35 to 53 wt.%, relative to the total weight of the matrix layer, and wherein the area density of the oral film is 50 to 300 g / m 2 , preferably 150 to 250 g / m 2 .

[0571] 70. An oral film for use according to any one of items 50 and 54 to 69, use of the oral film according to any one of items 51 and 54 to 69 in the preparation of a medicament, or a method of treatment according to any one of items 52 to 69, wherein the lurasidone or a pharmaceutically acceptable salt thereof contains a total amount of 15 mg to 55 mg, preferably 25 mg to 55 mg, most preferably about 40 mg of lurasidone hydrochloride.

[0572] 71. The oral film for use according to any one of items 50 and 54 to 70, the use of the oral film according to any one of items 51 and 54 to 70 in the preparation of a medicament, or the method of treatment according to any one of items 52 to 70, wherein the oral film has an in vitro disintegration time of 10 to 120 seconds, preferably 15 to 60 seconds.

[0573] 72. An oral film for use according to any one of items 50 and 54 to 71, use of the oral film according to any one of items 51 and 54 to 71 in the preparation of a medicament, or a method of treatment according to any one of items 52 to 71, wherein the oral film has a tensile strength of 3-15N, preferably 5-15N.

[0574] 73. An oral film for use according to any one of items 50 and 54 to 72, the use of the oral film according to any one of items 51 and 54 to 72 in the preparation of a medicament, or the method of treatment according to any one of items 52 to 72, wherein the oral film releases at least 80% of lurasidone or a pharmaceutically acceptable salt thereof within the first 15 minutes after being immersed in an aqueous solution at a temperature of 37±0.5°C and having a pH of 1.2 and / or releases at least 90% of lurasidone or a pharmaceutically acceptable salt thereof within the first 15 minutes after being immersed in an aqueous solution at a temperature of 37±0.5°C and having a pH of 3.8.

[0575] 74. The oral film according to any one of items 50 and 54 to 73, the use of the oral film according to any one of items 51 and 54 to 73 in the preparation of a medicament, or the method of treatment according to any one of items 52 to 73, wherein at least 70% or at least 80% of lurasidone or a pharmaceutically acceptable salt thereof is released within the first 15 minutes after immersion in an aqueous solution having a pH value of 3.8.

[0576] 75. The oral film for use according to any one of items 50 and 54 to 74, the use of the oral film of any one of items 51 and 54 to 74 in the preparation of a medicament, or the method of treatment according to any one of items 52 to 74, wherein the oral film comprises:

[0577] - 40 to 45 wt.% of lurasidone hydrochloride,

[0578] - 10 to 25 wt.% of polyvinyl alcohol-polyethylene glycol graft copolymer,

[0579] - 10 to 25 wt.% of polyvinyl alcohol having an average molecular weight of 20,000 to 40,000 g / mol,

[0580] - 4 to 10 wt.% of a plasticizer, in particular glycerol triacetate,

[0581] - 5 to 15 wt.% of a sweetener, preferably a mixture of sucralose, sorbitol and neotame,

[0582] - 2.5 to 7.5 wt. % of a first flavoring, in particular cherry flavoring,

[0583] - 0 to 2.5 wt.% of a second flavoring agent, in particular peppermint oil,

[0584] - 0 to 2 wt.% of colorants, especially erythrosine,

[0585] - 0.5 to 2 wt.% of emulsifier, in particular polyoxyethylene-(20)-sorbitan monooleate, and optionally residual process solvent, in particular water.

[0586] 76. An oral film for use according to any one of items 50 and 54 to 75, use of the oral film according to any one of items 51 and 54 to 75 in the preparation of a medicament, or a treatment method according to any one of items 52 to 75, wherein the oral film can be obtained by drying a coated coating composition comprising lurasidone, polyvinyl alcohol, a polyvinyl alcohol-polyethylene glycol graft copolymer and water.

Claims

1. An oral film comprising a matrix layer, wherein the matrix layer comprises lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol having an average molecular weight of 20,000 to 40,000 g / mol.

2. The oral film according to claim 1, wherein lurasidone or a pharmaceutically acceptable salt thereof is provided in the matrix layer in an amount of 35 to 55 wt.%, preferably 35 to 53 wt.%, more preferably 40 to 45 wt.%, relative to the total weight of the matrix layer.

3. The oral film according to claim 1 or 2, wherein at least one polyvinyl alcohol-polyethylene glycol graft copolymer has a polyethylene glycol backbone onto which polyvinyl alcohol units are grafted.

4. The oral film according to any one of the preceding claims, wherein the molar ratio of polyethylene glycol monomer units to polyvinyl alcohol monomer units is 1:

3.

5. The oral film according to any one of the preceding claims, wherein the at least one polyvinyl alcohol-polyethylene glycol graft copolymer has an average molecular weight ranging from 40,000 to 50,000 g / mol, preferably about 45,000 g / mol.

6. The oral film according to any one of the preceding claims, wherein at least one polyvinyl alcohol is provided in the matrix layer in an amount of 5 to 30 wt.%, preferably 10 to 25 wt.%, relative to the total weight of the matrix layer.

7. The oral film according to any one of the preceding claims, wherein at least one polyvinyl alcohol-polyethylene glycol graft copolymer is provided in the matrix layer in an amount of 5 to 35 wt.%, preferably 10 to 30 wt.%, relative to the total weight of the matrix layer.

8. The oral film according to any one of the preceding claims, wherein the at least one polyvinyl alcohol-polyethylene glycol graft copolymer and the at least one polyvinyl alcohol are present in a combined amount of 25 to 65 wt.%, preferably 30 to 60 wt.%, more preferably 30 to 45 wt.%, relative to the total weight of the matrix layer.

9. The oral film according to any one of the preceding claims, wherein the matrix layer comprises at least one plasticizer, preferably selected from polyethylene glycol, glycerol and triacetin, preferably wherein the at least one plasticizer is triacetin.

10. The oral film according to claim 9, wherein the plasticizer is present in an amount of 1 to 15 wt.%, preferably 4 to 10 wt.%, most preferably 5 to 10 wt.%.

11. The oral film according to any one of the preceding claims, wherein the matrix layer comprises at least one emulsifier, preferably selected from polyoxyethylene-(20)-sorbitan monooleate, polyoxyethylene-(20)-sorbitan monostearate, diacetyl esters of monoglycerides and diglycerides, most preferably wherein the emulsifier is polyoxyethylene-(20)-sorbitan monooleate.

12. The oral film according to any one of the preceding claims, wherein the matrix layer comprises at least one emulsifier in an amount of 0.1 to 2 wt.%, preferably 0.5 to 1.5 wt.%, based on the total weight of the matrix layer.

13. The oral film according to any one of the preceding claims, wherein the matrix layer further comprises at least one auxiliary substance selected from colorants, flavoring agents, sweeteners, taste masking agents, enhancers, pH adjusters, wetting agents, preservatives and / or antioxidants.

14. The oral film according to any one of the preceding claims, wherein lurasidone or a pharmaceutically acceptable salt thereof is present in the form of microparticles, preferably having -D 90 1 to 20 μm, preferably 1 to 10 μm, and / or -D 50 It is 0.1 to 25 μm, preferably 0.5 to 5 μm.

15. The oral film according to any one of the preceding claims, wherein lurasidone or a pharmaceutically acceptable salt thereof is substantially insoluble in the matrix layer.

16. The oral film according to any one of the preceding claims, wherein the oral film has an area density of 50 to 300 g / m 2 , preferably 150 to 250 g / m 2 .

17. The oral film according to any one of the preceding claims, wherein the lurasidone or a pharmaceutically acceptable salt thereof is provided in the matrix layer in an amount of 35 to 55 wt.%, preferably 35 to 53 wt.%, relative to the total weight of the matrix layer, and wherein the area density of the oral film is 50 to 300 g / m 2 , preferably 150 to 250 g / m 2 .

18. The oral film according to any one of the preceding claims, wherein lurasidone or a pharmaceutically acceptable salt thereof comprises a total amount of 15 to 55 mg, preferably 25 to 55 mg, and most preferably about 40 mg of lurasidone hydrochloride.

19. The oral film according to any one of the preceding claims, having an in vitro disintegration time of 10 to 120 seconds, preferably 15 to 60 seconds.

20. The oral film according to any one of the preceding claims, having a tensile strength of 3 to 15N, preferably 5 to 15N.

21. The oral film according to any one of the preceding claims, wherein at least 80% of lurasidone or a pharmaceutically acceptable salt thereof is released within the first 15 minutes after immersion in an aqueous solution at a temperature of 37±0.5°C and a pH of 1.2, and / or at least 90% of lurasidone or a pharmaceutically acceptable salt thereof is released within the first 15 minutes after immersion in an aqueous solution at a temperature of 37±0.5°C and a pH of 3.

8.

22. The oral film according to any one of the preceding claims, wherein at least 70% or at least 80% of lurasidone or a pharmaceutically acceptable salt thereof is released within the first 15 minutes of immersion in an aqueous solution having a pH of 3.

8.

23. The oral film according to any one of the preceding claims, wherein the oral film comprises: - 40 to 45 wt.% of lurasidone hydrochloride, - 10 to 25 wt.% of polyvinyl alcohol-polyethylene glycol graft copolymer, - 10 to 25 wt.% of polyvinyl alcohol having an average molecular weight of 20,000 to 40,000 g / mol, - 4 to 10 wt.% of a plasticizer, in particular glycerol triacetate, - 5 to 15 wt.% of a sweetener, preferably a mixture of sucralose, sorbitol and neotame, - 2.5 to 7.5 wt. % of a first flavoring, in particular cherry flavoring, - 0 to 2.5 wt.% of a second flavoring agent, in particular peppermint oil, - 0 to 2 wt.% of colorants, especially erythrosine, - 0.5 to 2 wt.% of an emulsifier, in particular polyoxyethylene-(20)-sorbitan monooleate, and optionally residual process solvent, in particular water.

24. The oral film according to any one of the preceding claims, wherein the oral film is obtainable by drying a coated coating composition comprising lurasidone, polyvinyl alcohol, a polyvinyl alcohol-polyethylene glycol graft copolymer and water.

25. A method for preparing an oral film: a) preparing a dispersion comprising lurasidone or a pharmaceutically acceptable salt thereof, at least one polyvinyl alcohol-polyethylene glycol graft copolymer and at least one polyvinyl alcohol having an average molecular weight of 20,000 to 40,000 g / mol; b) spreading the dispersion from step a), c) drying the spread dispersion from step b) to obtain the matrix layer of the oral film.

26. Use of an oral film according to any one of claims 1 to 24 or obtainable by a process according to claim 25 for the preparation of a medicament.

27. Use of an oral film according to any one of claims 1 to 24 or obtainable by a process according to claim 25 for the preparation of a medicament for the treatment of psychiatric disorders, in particular schizophrenia, depression and / or bipolar disorder.

Citation Information

Patent Citations

  • Lurasidone hydrochloride oral instant film preparation and preparation method thereof

    CN112618518A

  • Oral film

    CN114452269A